|
G |
A1cf |
APOBEC1 complementation factor |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of A1CF mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:229,736,037...229,823,499
|
|
G |
Aaas |
aladin WD repeat nucleoporin |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of AAAS mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 7:133,464,315...133,483,961
|
|
G |
Aasdh |
aminoadipate-semialdehyde dehydrogenase |
affects expression |
ISO |
benz(a)anthracene affects the expression of AASDH mRNA |
CTD |
PMID:26377693 |
|
NCBI chr14:31,255,019...31,281,802
|
|
G |
Aatk |
apoptosis-associated tyrosine kinase |
increases expression |
ISO |
benz(a)anthracene results in increased expression of AATK mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:105,789,171...105,825,634
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ABCC3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:79,793,571...79,839,528
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of ABCC5 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ABCC5 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr11:93,975,579...94,071,659
|
|
G |
Abcc9 |
ATP binding cassette subfamily C member 9 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of ABCC9 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:177,262,848...177,386,837
|
|
G |
Abhd15 |
abhydrolase domain containing 15 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ABHD15 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:62,363,209...62,368,600
|
|
G |
Abhd6 |
abhydrolase domain containing 6, acylglycerol lipase |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ABHD6 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr15:16,859,740...16,907,094
|
|
G |
Abi3bp |
ABI family member 3 binding protein |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ABI3BP mRNA |
CTD |
PMID:27858113 |
|
NCBI chr11:43,912,187...44,128,888
|
|
G |
Ablim1 |
actin-binding LIM protein 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ABLIM1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:266,088,868...266,377,169
|
|
G |
Abraxas2 |
abraxas 2, BRISC complex subunit |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of ABRAXAS2 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ABRAXAS2 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 1:187,647,078...187,672,660
|
|
G |
Accs |
1-aminocyclopropane-1-carboxylate synthase |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ACCS mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:79,805,254...79,820,830
|
|
G |
Acin1 |
apoptotic chromatin condensation inducer 1 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of ACIN1 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ACIN1 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr15:32,072,121...32,117,004
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ACOT1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 6:103,636,173...103,644,167
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of ACOX1 mRNA; benz(a)anthracene results in increased expression of ACOX1 protein benz(a)anthracene promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide] |
CTD |
PMID:10497882 |
|
NCBI chr10:101,905,083...101,930,136
|
|
G |
Acoxl |
acyl-CoA oxidase-like |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of ACOXL mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ACOXL mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 3:115,061,069...115,367,032
|
|
G |
Acrbp |
acrosin binding protein |
affects expression |
ISO |
benz(a)anthracene affects the expression of ACRBP mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:157,851,149...157,864,211
|
|
G |
Acvr1b |
activin A receptor type 1B |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ACVR1B mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 7:134,164,987...134,208,389
|
|
G |
Adam22 |
ADAM metallopeptidase domain 22 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ADAM22 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:25,716,055...25,970,932
|
|
G |
Adamdec1 |
ADAM-like, decysin 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ADAMDEC1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr15:42,900,629...42,921,684
|
|
G |
Adamts14 |
ADAM metallopeptidase with thrombospondin type 1 motif, 14 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ADAMTS14 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr20:29,143,029...29,219,846
|
|
G |
Adcy7 |
adenylate cyclase 7 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ADCY7 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr19:34,913,154...34,972,366
|
|
G |
Add3 |
adducin 3 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ADD3 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:262,152,722...262,260,504
|
|
G |
Adgre4 |
adhesion G protein-coupled receptor E4 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ADGRE4 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 9:9,758,106...9,901,908
|
|
G |
Adgrl4 |
adhesion G protein-coupled receptor L4 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ADGRL4 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 2:240,354,909...240,457,231
|
|
G |
Adm |
adrenomedullin |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of ADM mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ADM mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 1:174,164,178...174,182,372
|
|
G |
Adora1 |
adenosine A1 receptor |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ADORA1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr13:45,658,872...45,695,821
|
|
G |
Adra1b |
adrenoceptor alpha 1B |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of ADRA1B mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:28,255,025...28,373,418
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
affects expression |
ISO |
benz(a)anthracene affects the expression of ADRB3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr16:64,839,820...64,844,552
|
|
G |
Aen |
apoptosis enhancing nuclease |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of AEN mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:132,815,094...132,824,522
|
|
G |
Agbl2 |
AGBL carboxypeptidase 2 |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of AGBL2 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AGBL2 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 3:76,764,893...76,800,071
|
|
G |
Ago2 |
argonaute RISC catalytic component 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AGO2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 7:106,907,209...106,994,124
|
|
G |
Ago4 |
argonaute RISC component 4 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of AGO4 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:138,780,446...138,825,898
|
|
G |
Agrp |
agouti related neuropeptide |
increases expression |
ISO |
benz(a)anthracene results in increased expression of AGRP mRNA |
CTD |
PMID:26377693 |
|
NCBI chr19:33,447,992...33,481,602
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
increases expression |
ISO |
benz(a)anthracene results in increased expression of AGTR1A mRNA |
CTD |
PMID:26377693 |
|
NCBI chr17:34,383,397...34,435,523
|
|
G |
Ahcyl2 |
adenosylhomocysteinase-like 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AHCYL2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 4:58,381,290...58,531,061
|
|
G |
Ahnak |
AHNAK nucleoprotein |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of AHNAK mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AHNAK mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 1:205,882,225...205,970,934
|
|
G |
Ahnak2 |
AHNAK nucleoprotein 2 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of AHNAK2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 6:131,830,668...131,876,311
|
|
G |
Ahr |
aryl hydrocarbon receptor |
affects response to substance increases activity increases response to substance multiple interactions affects binding |
ISO EXP |
AHR affects the susceptibility to benz(a)anthracene benz(a)anthracene results in increased activity of AHR protein AHR results in increased susceptibility to benz(a)anthracene [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with 1,2,5,6-dibenzanthracene co-treated with pyrene] results in increased activity of AHR protein; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [indeno(1,2,3-cd)pyrene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene] promotes the reaction [pyrene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with pyrene] promotes the reaction [fluoranthene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [chrysene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [benzo(k)fluoranthene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [benzo(j)fluoranthene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [Benzo(a)pyrene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with TNF protein] results in increased activity of AHR protein; [Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [benz(a)anthracene results in increased activity of AHR protein]; AHR protein affects the reaction [[benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6]; AHR protein affects the reaction [benz(a)anthracene results in increased expression of CYP1B1 mRNA]; AHR protein promotes the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; benz(a)anthracene promotes the reaction [AHR protein results in increased expression of CYP1A1 mRNA] benz(a)anthracene binds to AHR protein AHR protein affects the reaction [benz(a)anthracene inhibits the reaction [EGF protein binds to EGFR protein]]; benz(a)anthracene binds to and results in increased activity of AHR protein; benz(a)anthracene inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein] AHR affects the reaction [benz(a)anthracene results in increased expression of CCNA2 protein]; AHR affects the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]; benz(a)anthracene binds to and results in increased activity of AHR protein; benz(a)anthracene inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein] |
CTD |
PMID:1650214 PMID:1654865 PMID:1658612 PMID:2154949 PMID:3005314 PMID:3024361 PMID:6309801 PMID:12117779 PMID:12850102 PMID:15071172 PMID:17141280 PMID:17665671 PMID:18205319 PMID:20634293 PMID:21781905 PMID:23396138 PMID:25329374 More...
|
|
NCBI chr 6:57,961,423...57,998,901
|
|
G |
Ahrr |
aryl-hydrocarbon receptor repressor |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of AHRR mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of AHRR mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 1:28,993,634...29,088,673
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AIF1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr20:3,651,435...3,657,341
|
|
G |
Aifm3 |
AIF family member 3 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of AIFM3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr11:83,504,859...83,523,630
|
|
G |
Akap13 |
A-kinase anchoring protein 13 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of AKAP13 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:129,313,183...129,619,647
|
|
G |
Akap7 |
A-kinase anchoring protein 7 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AKAP7 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:21,906,503...22,168,663
|
|
G |
Akap8 |
A-kinase anchoring protein 8 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of AKAP8 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 7:11,316,224...11,332,523
|
|
G |
Akap8l |
A-kinase anchoring protein 8 like |
increases expression |
ISO |
benz(a)anthracene results in increased expression of AKAP8L mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 7:11,332,671...11,362,287
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of AKR1B10 mRNA |
CTD |
PMID:22236718 |
|
NCBI chr 4:64,005,632...64,027,860
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of AKR1C1 mRNA |
CTD |
PMID:17253728 PMID:22236718 |
|
NCBI chr17:70,720,397...70,747,285
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of AKR1C3 mRNA |
CTD |
PMID:22236718 |
|
NCBI chr17:71,020,884...71,037,779
|
|
G |
Aldh1l1 |
aldehyde dehydrogenase 1 family, member L1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of ALDH1L1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:123,059,989...123,106,471
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ALDH3A1 mRNA |
CTD |
PMID:32890658 |
|
NCBI chr10:46,392,464...46,402,151
|
|
G |
Alg6 |
ALG6, alpha-1,3-glucosyltransferase |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ALG6 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:119,520,415...119,606,365
|
|
G |
Alkal1 |
ALK and LTK ligand 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ALKAL1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:13,019,729...13,049,913
|
|
G |
Alox12 |
arachidonate 12-lipoxygenase, 12S type |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ALOX12 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:54,958,263...54,970,542
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ALOX5 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:151,203,948...151,251,126
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ALPL mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:155,234,770...155,289,785
|
|
G |
Als2cl |
ALS2 C-terminal like |
affects expression |
ISO |
benz(a)anthracene affects the expression of ALS2CL mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:110,863,753...110,884,434
|
|
G |
Amdhd2 |
amidohydrolase domain containing 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of AMDHD2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:13,187,579...13,196,148
|
|
G |
Angpt2 |
angiopoietin 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ANGPT2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr16:71,088,364...71,138,805
|
|
G |
Angptl4 |
angiopoietin-like 4 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANGPTL4 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 7:14,550,288...14,557,797
|
|
G |
Ank3 |
ankyrin 3 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANK3 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr20:18,602,267...19,225,831
|
|
G |
Ankrd12 |
ankyrin repeat domain 12 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANKRD12 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 9:105,583,273...105,687,957
|
|
G |
Ankrd16 |
ankyrin repeat domain 16 |
affects expression |
ISO |
benz(a)anthracene affects the expression of ANKRD16 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr17:66,735,325...66,748,533
|
|
G |
Ankzf1 |
ankyrin repeat and zinc finger peptidyl tRNA hydrolase 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ANKZF1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 9:76,688,194...76,695,162
|
|
G |
Anp32a |
acidic nuclear phosphoprotein 32 family member A |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ANP32A mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:62,829,099...62,865,443
|
|
G |
Anpep |
alanyl aminopeptidase, membrane |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANPEP mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:143,176,645...143,219,447
|
|
G |
Anxa10 |
annexin A10 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ANXA10 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr16:27,738,712...27,805,648
|
|
G |
Ap5s1 |
adaptor related protein complex 5 subunit sigma 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of AP5S1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:118,429,618...118,432,929
|
|
G |
Ap5z1 |
adaptor related protein complex 5 subunit zeta 1 |
affects expression |
ISO |
benz(a)anthracene affects the expression of AP5Z1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr12:12,093,834...12,109,043
|
|
G |
Apbb3 |
amyloid beta precursor protein binding family B member 3 |
affects expression |
ISO |
benz(a)anthracene affects the expression of APBB3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr18:28,547,205...28,554,383
|
|
G |
Apobec3 |
apolipoprotein B mRNA editing enzyme catalytic subunit 3 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of APOBEC3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 7:111,433,789...111,453,032
|
|
G |
Apol9a |
apolipoprotein L9a |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of APOL9A mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of APOL9A mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 7:109,140,871...109,149,799
|
|
G |
Appl2 |
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of APPL2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 7:20,135,248...20,184,757
|
|
G |
Aqp4 |
aquaporin 4 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of AQP4 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr18:6,782,389...6,799,034
|
|
G |
Ar |
androgen receptor |
increases activity multiple interactions |
EXP ISO |
benz(a)anthracene results in increased activity of AR protein benz(a)anthracene binds to and results in decreased activity of AR protein; benz(a)anthracene inhibits the reaction [Androgens results in increased activity of AR protein] |
CTD |
PMID:10771140 PMID:28377212 |
|
NCBI chr X:63,104,771...63,273,934
|
|
G |
Arap2 |
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of ARAP2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr14:50,921,323...51,120,972
|
|
G |
Areg |
amphiregulin |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of AREG mRNA bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of AREG mRNA]]; Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of AREG mRNA] [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AREG mRNA |
CTD |
PMID:22643241 PMID:27858113 |
|
NCBI chr14:17,256,384...17,265,641
|
|
G |
Arglu1 |
arginine and glutamate rich 1 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of ARGLU1 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARGLU1 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr16:87,455,097...87,479,148
|
|
G |
Arhgap20 |
Rho GTPase activating protein 20 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of ARHGAP20 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:52,074,472...52,155,739
|
|
G |
Arhgap23 |
Rho GTPase activating protein 23 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of ARHGAP23 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:82,891,021...82,993,230
|
|
G |
Arhgap4 |
Rho GTPase activating protein 4 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ARHGAP4 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr X:151,636,071...151,651,528
|
|
G |
Arhgap45 |
Rho GTPase activating protein 45 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ARHGAP45 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 7:9,674,873...9,690,286
|
|
G |
Arhgef38 |
Rho guanine nucleotide exchange factor 38 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARHGEF38 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 2:221,610,212...221,739,841
|
|
G |
Arhgef40 |
Rho guanine nucleotide exchange factor 40 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ARHGEF40 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr15:24,672,645...24,696,510
|
|
G |
Arid4a |
AT-rich interaction domain 4A |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of ARID4A mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 6:95,258,429...95,335,987
|
|
G |
Arih2 |
ariadne RBR E3 ubiquitin protein ligase 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ARIH2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:118,175,267...118,234,425
|
|
G |
Arl5c |
ARF like GTPase 5C |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ARL5C mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:82,985,213...82,993,425
|
|
G |
Armc6 |
armadillo repeat containing 6 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARMC6 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr16:19,191,106...19,201,528
|
|
G |
Arrdc2 |
arrestin domain containing 2 |
affects expression |
ISO |
benz(a)anthracene affects the expression of ARRDC2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr16:18,601,897...18,606,029
|
|
G |
Arrdc4 |
arrestin domain containing 4 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARRDC4 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:122,369,355...122,383,351
|
|
G |
Art4 |
ADP-ribosyltransferase 4 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ART4 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:171,468,415...171,482,435
|
|
G |
Ascc3 |
activating signal cointegrator 1 complex subunit 3 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of ASCC3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr20:53,510,137...53,795,446
|
|
G |
Asgr1 |
asialoglycoprotein receptor 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of ASGR1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:54,775,727...54,779,642
|
|
G |
Asgr2 |
asialoglycoprotein receptor 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ASGR2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr10:54,821,407...54,834,624
|
|
G |
Asph |
aspartate-beta-hydroxylase |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of ASPH mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ASPH mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 5:27,398,933...27,611,519
|
|
G |
Atad2b |
ATPase family, AAA domain containing 2B |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of ATAD2B mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 6:27,914,546...28,070,103
|
|
G |
Atg16l2 |
autophagy related 16-like 2 |
affects expression |
ISO |
benz(a)anthracene affects the expression of ATG16L2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:155,687,386...155,703,419
|
|
G |
Atosa |
atos homolog A |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ATOSA mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:75,694,828...75,772,565
|
|
G |
Atp11a |
ATPase phospholipid transporting 11A |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ATP11A mRNA |
CTD |
PMID:26377693 |
|
NCBI chr16:76,657,752...76,767,640
|
|
G |
Atp13a3 |
ATPase 13A3 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ATP13A3 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr11:70,364,998...70,442,005
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of ATP2A2 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ATP2A2 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr12:34,072,710...34,122,142
|
|
G |
Atp6v0e2 |
ATPase, H+ transporting V0 subunit e2 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of ATP6V0E2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:77,484,868...77,488,016
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of AVPR1A mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 7:59,999,743...60,003,667
|
|
G |
Azin1 |
antizyme inhibitor 1 |
affects expression |
ISO |
benz(a)anthracene affects the expression of AZIN1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 7:69,654,773...69,681,578
|
|
G |
B4galt1 |
beta-1,4-galactosyltransferase 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of B4GALT1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 5:55,935,614...55,982,461
|
|
G |
B4galt5 |
beta-1,4-galactosyltransferase 5 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of B4GALT5 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:156,018,056...156,033,983
|
|
G |
Baat |
bile acid CoA:amino acid N-acyltransferase |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of BAAT mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:68,647,166...68,656,137
|
|
G |
Bach2 |
BTB domain and CNC homolog 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of BACH2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:46,632,338...46,982,676
|
|
G |
Bag3 |
BAG cochaperone 3 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of BAG3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:192,533,460...192,557,281
|
|
G |
Bank1 |
B-cell scaffold protein with ankyrin repeats 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of BANK1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 2:224,530,475...224,800,420
|
|
G |
Banp |
Btg3 associated nuclear protein |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of BANP mRNA |
CTD |
PMID:26377693 |
|
NCBI chr19:50,007,710...50,082,742
|
|
G |
Batf |
basic leucine zipper ATF-like transcription factor |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BATF mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 6:111,084,717...111,107,052
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BAX mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:105,076,472...105,081,906
|
|
G |
Bcl2l14 |
Bcl2-like 14 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of BCL2L14 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:167,217,561...167,258,723
|
|
G |
Bcl3 |
BCL3, transcription coactivator |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BCL3 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:79,471,368...79,485,908
|
|
G |
Bcl6b |
BCL6B, transcription repressor |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BCL6B mRNA |
CTD |
PMID:27858113 |
|
NCBI chr10:54,940,908...54,947,022
|
|
G |
Bcl7b |
BAF chromatin remodeling complex subunit BCL7B |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BCL7B mRNA |
CTD |
PMID:27858113 |
|
NCBI chr12:27,133,412...27,146,631
|
|
G |
Bclaf1 |
BCL2-associated transcription factor 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of BCLAF1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:16,904,572...16,937,106
|
|
G |
Bend3 |
BEN domain containing 3 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of BEND3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr20:46,980,246...47,017,059
|
|
G |
Bfsp2 |
beaded filament structural protein 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of BFSP2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:104,006,226...104,063,399
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BHLHE40 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 4:141,618,453...141,624,154
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BIRC5 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr10:103,567,369...103,580,069
|
|
G |
Bloc1s2 |
biogenesis of lysosomal organelles complex-1, subunit 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BLOC1S2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:252,973,818...252,980,873
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of BMAL1 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BMAL1 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 1:176,766,222...176,864,741
|
|
G |
Bmf |
Bcl2 modifying factor |
increases expression |
ISO |
benz(a)anthracene results in increased expression of BMF mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:125,953,466...125,974,087
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of BMP7 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:182,059,318...182,135,273
|
|
G |
Bmpr2 |
bone morphogenetic protein receptor type 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BMPR2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 9:68,685,942...68,801,353
|
|
G |
Bmx |
BMX non-receptor tyrosine kinase |
increases expression |
ISO |
benz(a)anthracene results in increased expression of BMX mRNA |
CTD |
PMID:26377693 |
|
NCBI chr X:33,859,128...33,921,876
|
|
G |
Brwd1 |
bromodomain and WD repeat domain containing 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of BRWD1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr11:48,756,174...48,853,692
|
|
G |
Bscl2 |
BSCL2 lipid droplet biogenesis associated, seipin |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BSCL2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:205,731,828...205,743,430
|
|
G |
Btg1 |
BTG anti-proliferation factor 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of BTG1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 7:33,228,149...33,230,406
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of BTG2 mRNA |
CTD |
PMID:22236718 |
|
NCBI chr13:48,083,931...48,087,690
|
|
G |
Btla |
B and T lymphocyte associated |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of BTLA mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BTLA mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr11:69,069,734...69,099,331
|
|
G |
C2 |
complement C2 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of C2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr20:3,951,474...3,970,376
|
|
G |
C2cd3 |
C2 domain containing 3 centriole elongation regulator |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of C2CD3 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of C2CD3 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 1:164,127,304...164,225,088
|
|
G |
C5 |
complement C5 |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of HC mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HC mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 3:38,668,174...38,759,468
|
|
G |
C5ar2 |
complement C5a receptor 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of C5AR2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:76,930,381...76,945,432
|
|
G |
C7 |
complement C7 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of C7 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 2:54,088,116...54,165,102
|
|
G |
Cabp5 |
calcium binding protein 5 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CABP5 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:74,350,811...74,363,830
|
|
G |
Cacna1i |
calcium voltage-gated channel subunit alpha1 I |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CACNA1I mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 7:113,716,266...113,827,670
|
|
G |
Cacybp |
calcyclin binding protein |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of CACYBP mRNA |
CTD |
PMID:26377693 |
|
NCBI chr13:74,970,917...74,981,298
|
|
G |
Calcr |
calcitonin receptor |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CALCR mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:31,661,270...31,736,392
|
|
G |
Camk2g |
calcium/calmodulin-dependent protein kinase II gamma |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CAMK2G mRNA |
CTD |
PMID:26377693 |
|
NCBI chr15:3,553,238...3,612,310
|
|
G |
Capn11 |
calpain 11 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CAPN11 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 9:15,344,059...15,365,604
|
|
G |
Caps2 |
calcyphosine 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CAPS2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 7:47,580,636...47,641,598
|
|
G |
Car14 |
carbonic anhydrase 14 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of CAR14 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CAR14 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 2:183,442,263...183,449,231
|
|
G |
Card11 |
caspase recruitment domain family, member 11 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CARD11 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr12:18,735,088...18,872,045
|
|
G |
Cav1 |
caveolin 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CAV1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 4:46,606,538...46,639,616
|
|
G |
Cbfa2t3 |
CBFA2/RUNX1 partner transcriptional co-repressor 3 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CBFA2T3 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr19:50,679,897...50,750,028
|
|
G |
Ccbe1 |
collagen and calcium binding EGF domains 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCBE1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr18:61,849,821...62,093,876
|
|
G |
Ccdc121 |
coiled-coil domain containing 121 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CCDC121 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 6:24,970,845...24,973,451
|
|
G |
Ccdc184 |
coiled-coil domain containing 184 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCDC184 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 7:129,297,635...129,301,961
|
|
G |
Ccdc28b |
coiled coil domain containing 28B |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CCDC28B mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:141,962,275...141,967,278
|
|
G |
Ccdc30 |
coiled-coil domain containing 30 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CCDC30 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:132,926,767...133,019,635
|
|
G |
Ccdc39 |
coiled-coil domain 39 molecular ruler complex subunit |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CCDC39 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 2:116,665,651...116,703,354
|
|
G |
Ccdc68 |
coiled-coil domain containing 68 |
affects expression |
ISO |
benz(a)anthracene affects the expression of CCDC68 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr18:63,541,828...63,584,122
|
|
G |
Ccdc78 |
coiled-coil domain containing 78 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CCDC78 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:14,808,355...14,812,284
|
|
G |
Ccdc81 |
coiled-coil domain containing 81 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CCDC81 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:143,739,472...143,791,026
|
|
G |
Ccdc82 |
coiled-coil domain containing 82 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CCDC82 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:18,509,293...18,665,008
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CCL11 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:67,525,975...67,530,576
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[benz(a)anthracene co-treated with TNF protein] results in increased expression of CCL2 mRNA |
CTD |
PMID:23396138 |
|
NCBI chr10:67,503,077...67,504,875
|
|
G |
Ccl27 |
C-C motif chemokine ligand 27 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of CCL27A mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:56,941,402...56,948,511
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCL4 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr10:68,963,893...68,965,728
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCL5 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr10:68,820,330...68,824,906
|
|
G |
Ccl9 |
C-C motif chemokine ligand 9 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCL6 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr10:68,863,994...68,868,928
|
|
G |
Ccm2l |
CCM2 like scaffold protein |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of CCM2L mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCM2L mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 3:141,533,470...141,549,136
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions increases expression |
EXP |
AHR affects the reaction [benz(a)anthracene results in increased expression of CCNA2 protein]; benz(a)anthracene results in increased activity of [CCNA2 protein binds to CDK2 protein] |
CTD |
PMID:17141280 |
|
NCBI chr 2:121,355,363...121,361,762
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCND1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:209,518,288...209,527,986
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCND2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 4:161,653,048...161,675,422
|
|
G |
Ccng1 |
cyclin G1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCNG1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr10:25,678,503...25,684,876
|
|
G |
Ccnjl |
cyclin J-like |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of CCNJL mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCNJL mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr10:27,995,682...28,053,428
|
|
G |
Ccnl1 |
cyclin L1 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of CCNL1 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCNL1 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 2:152,495,169...152,508,855
|
|
G |
Ccnl2 |
cyclin L2 |
affects expression |
ISO |
benz(a)anthracene affects the expression of CCNL2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:171,698,951...171,711,037
|
|
G |
Ccr3 |
C-C motif chemokine receptor 3 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CCR3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:123,586,100...123,634,178
|
|
G |
Ccr6 |
C-C motif chemokine receptor 6 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CCR6 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:55,022,037...55,055,857
|
|
G |
Ccr7 |
C-C motif chemokine receptor 7 |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of CCR7 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCR7 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr10:84,098,193...84,108,309
|
|
G |
Cd151 |
CD151 molecule (Raph blood group) |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of CD151 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD151 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 1:205,994,300...205,998,307
|
|
G |
Cd19 |
CD19 molecule |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CD19 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:190,417,853...190,424,494
|
|
G |
Cd200 |
Cd200 molecule |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD200 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr11:68,916,200...68,943,570
|
|
G |
Cd300c2 |
CD300C molecule 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CD300C2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:100,253,312...100,258,553
|
|
G |
Cd300lf |
Cd300 molecule-like family member F |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CD300LF mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:100,359,942...100,376,130
|
|
G |
Cd34 |
CD34 molecule |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD34 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr13:109,008,786...109,029,317
|
|
G |
Cd37 |
CD37 molecule |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD37 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:95,719,171...95,724,662
|
|
G |
Cd48 |
Cd48 molecule |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD48 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr13:86,717,960...86,741,540
|
|
G |
Cd69 |
Cd69 molecule |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of CD69 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD69 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 4:164,411,485...164,419,403
|
|
G |
Cd79a |
CD79a molecule |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CD79A mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:89,621,460...89,625,813
|
|
G |
Cd79b |
CD79b molecule |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of CD79B mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD79B mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr10:91,739,134...91,742,312
|
|
G |
Cd84 |
CD84 molecule |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CD84 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr13:84,327,580...84,367,153
|
|
G |
Cd8b |
CD8 subunit beta |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CD8B1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:104,870,911...104,886,838
|
|
G |
Cd99 |
CD99 molecule (Xg blood group) |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CD99 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr20:56,000,494...56,005,140
|
|
G |
Cdc14b |
cell division cycle 14B |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CDC14B mRNA |
CTD |
PMID:26377693 |
|
NCBI chr17:850,272...938,972
|
|
G |
Cdc40 |
cell division cycle 40 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of CDC40 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr20:44,273,080...44,325,605
|
|
G |
Cdh1 |
cadherin 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of CDH1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr19:51,402,178...51,471,572
|
|
G |
Cdh16 |
cadherin 16 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CDH16 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr19:360,824...371,008
|
|
G |
Cdhr4 |
cadherin-related family member 4 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CDHR4 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 8:108,682,594...108,690,358
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
EXP |
benz(a)anthracene results in increased activity of [CCNA2 protein binds to CDK2 protein] |
CTD |
PMID:17141280 |
|
NCBI chr 7:1,714,392...1,721,964
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression decreases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of CDKN1A mRNA benz(a)anthracene results in decreased expression of CDKN1A mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CDKN1A mRNA |
CTD |
PMID:22236718 PMID:26377693 PMID:27858113 |
|
NCBI chr20:7,150,820...7,161,373
|
|
G |
Celf5 |
CUGBP, Elav-like family member 5 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CELF5 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 7:8,225,787...8,250,322
|
|
G |
Celsr2 |
cadherin, EGF LAG seven-pass G-type receptor 2 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of CELSR2 mRNA |
CTD |
PMID:21635667 |
|
NCBI chr 2:196,029,206...196,053,848
|
|
G |
Cep162 |
centrosomal protein 162 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CEP162 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 8:88,149,726...88,208,249
|
|
G |
Cep70 |
centrosomal protein 70 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CEP70 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:99,810,270...99,863,279
|
|
G |
Cep85l |
centrosomal protein 85-like |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of CEP85L mRNA |
CTD |
PMID:26377693 |
|
NCBI chr20:32,568,417...32,739,449
|
|
G |
Cep95 |
centrosomal protein 95 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CEP95 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:91,732,111...91,760,095
|
|
G |
Ces2c |
carboxylesterase 2C |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CES2C mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:260,391,190...260,398,757
|
|
G |
Ces2e |
carboxylesterase 2E |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CES2E mRNA |
CTD |
PMID:27858113 |
|
NCBI chr19:157,447...172,822
|
|
G |
Cfap43 |
cilia and flagella associated protein 43 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CFAP43 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:246,625,259...246,712,438
|
|
G |
Cfap65 |
cilia and flagella associated protein 65 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CFAP65 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 9:76,459,211...76,494,199
|
|
G |
Cfb |
complement factor B |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CFB mRNA |
CTD |
PMID:27858113 |
|
NCBI chr20:3,970,643...3,976,510
|
|
G |
Cfl1 |
cofilin 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CFL1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:212,227,124...212,230,656
|
|
G |
Cgn |
cingulin |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CGN mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 2:182,308,389...182,335,747
|
|
G |
Chd2 |
chromodomain helicase DNA binding protein 2 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of CHD2 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CHD2 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 1:136,597,993...136,726,874
|
|
G |
Chia |
chitinase, acidic |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CHIA mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 2:196,302,687...196,344,849
|
|
G |
Chka |
choline kinase alpha |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of CHKA mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:210,506,069...210,554,753
|
|
G |
Chkb |
choline kinase beta |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CHKB mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 7:122,380,592...122,385,102
|
|
G |
Chmp4b |
charged multivesicular body protein 4B |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of CHMP4B mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:143,170,859...143,211,376
|
|
G |
Chordc1 |
cysteine and histidine rich domain containing 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of CHORDC1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:15,374,356...15,398,436
|
|
G |
Chpf2 |
chondroitin polymerizing factor 2 |
affects expression |
ISO |
benz(a)anthracene affects the expression of CHPF2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:10,578,470...10,585,940
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of CHRNA4 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:168,136,246...168,157,839
|
|
G |
Chst1 |
carbohydrate sulfotransferase 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CHST1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 3:78,552,059...78,574,740
|
|
G |
Chst3 |
carbohydrate sulfotransferase 3 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CHST3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr20:28,114,386...28,152,046
|
|
G |
Chst8 |
carbohydrate sulfotransferase 8 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CHST8 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:87,294,144...87,435,900
|
|
G |
Ciart |
circadian associated repressor of transcription |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CIART mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 2:183,419,819...183,424,845
|
|
G |
Cib3 |
calcium and integrin binding family member 3 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of CIB3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr16:17,622,431...17,631,827
|
|
G |
Cimap2 |
ciliary microtubule associated protein 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CIMAP2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:121,375,998...121,401,869
|
|
G |
Cirbp |
cold inducible RNA binding protein |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of CIRBP mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CIRBP mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 7:10,184,515...10,189,623
|
|
G |
Cish |
cytokine inducible SH2-containing protein |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of CISH mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:116,850,969...116,855,917
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CITED2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:12,312,426...12,314,869
|
|
G |
Ckap2 |
cytoskeleton associated protein 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CKAP2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr16:76,542,114...76,567,297
|
|
G |
Clasrp |
CLK4-associating serine/arginine rich protein |
increases expression |
ISO |
benz(a)anthracene results in increased expression of SFRS16 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:79,232,260...79,256,462
|
|
G |
Cldn1 |
claudin 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of CLDN1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr11:87,926,376...87,941,533
|
|
G |
Cldn17 |
claudin 17 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of CLDN17 mRNA |
CTD |
PMID:21635667 |
|
NCBI chr11:27,827,454...27,828,630
|
|
G |
Cldn2 |
claudin 2 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of CLDN2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr X:103,459,870...103,473,794
|
|
G |
Cldnd1 |
claudin domain containing 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of CLDND1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr11:41,883,120...41,889,471
|
|
G |
Clec1a |
C-type lectin domain family 1, member A |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of CLEC1A mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLEC1A mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 4:162,875,360...162,902,571
|
|
G |
Clec4a1 |
C-type lectin domain family 4, member A1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLEC4A1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 4:156,173,894...156,186,009
|
|
G |
Clec4g |
C-type lectin domain family 4, member G |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CLEC4G mRNA |
CTD |
PMID:27858113 |
|
NCBI chr12:1,780,370...1,785,027
|
|
G |
Clip4 |
CAP-GLY domain containing linker protein family, member 4 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CLIP4 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 6:23,616,280...23,697,625 NCBI chr 6:23,718,580...23,729,231 NCBI chr 6:23,597,729...23,601,000
|
|
G |
Clk1 |
CDC-like kinase 1 |
affects expression |
ISO |
benz(a)anthracene affects the expression of CLK1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 9:67,441,962...67,453,180
|
|
G |
Clk2 |
CDC-like kinase 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CLK2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 2:176,868,423...176,880,412
|
|
G |
Clk4 |
CDC-like kinase 4 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CLK4 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:36,024,364...36,042,366
|
|
G |
Clmn |
calmin |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CLMN mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 6:123,707,710...123,807,283
|
|
G |
Clmp |
CXADR-like membrane protein |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of CLMP mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:41,060,527...41,168,841
|
|
G |
Clock |
clock circadian regulator |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of CLOCK mRNA |
CTD |
PMID:26377693 |
|
NCBI chr14:32,262,747...32,346,872
|
|
G |
Clstn2 |
calsyntenin 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLSTN2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 8:98,020,406...98,637,232
|
|
G |
Cmpk2 |
cytidine/uridine monophosphate kinase 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CMPK2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 6:48,802,150...48,813,652
|
|
G |
Cntrl |
centriolin |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CNTRL mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:18,428,147...18,500,362
|
|
G |
Cobl |
cordon-bleu WH2 repeat protein |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of COBL mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COBL mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr14:86,828,137...87,060,682
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL1A1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr10:80,380,458...80,397,461
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL1A2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 4:33,518,557...33,553,484
|
|
G |
Col20a1 |
collagen type XX alpha 1 chain |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of COL20A1 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COL20A1 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 3:168,102,475...168,134,759
|
|
G |
Col27a1 |
collagen type XXVII alpha 1 chain |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of COL27A1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:76,647,302...76,765,989
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of COL2A1 mRNA |
CTD |
PMID:21635667 |
|
NCBI chr 7:130,977,561...131,006,627
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL3A1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 9:54,866,646...54,902,578
|
|
G |
Col4a4 |
collagen type IV alpha 4 chain |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of COL4A4 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL4A4 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 9:83,833,173...83,875,436
|
|
G |
Col4a6 |
collagen type IV alpha 6 chain |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of COL4A6 mRNA |
CTD |
PMID:21635667 |
|
NCBI chr X:109,554,945...109,905,987
|
|
G |
Col5a3 |
collagen type V alpha 3 chain |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of COL5A3 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL5A3 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 8:19,304,564...19,349,809
|
|
G |
Commd3 |
COMM domain containing 3 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COMMD3 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr17:81,327,444...81,331,191
|
|
G |
Coq10b |
coenzyme Q10B |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COQ10B mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 9:56,553,751...56,573,671
|
|
G |
Coq8a |
coenzyme Q8A |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COQ8A mRNA |
CTD |
PMID:27858113 |
|
NCBI chr13:94,436,680...94,465,535
|
|
G |
Coro2a |
coronin 2A |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CORO2A mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 5:60,825,630...60,881,917
|
|
G |
Cplx2 |
complexin 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CPLX2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr17:10,219,577...10,292,835
|
|
G |
Cpne4 |
copine 4 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CPNE4 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 8:105,177,376...105,653,075
|
|
G |
Cpne5 |
copine 5 |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of CPNE5 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CPNE5 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr20:7,206,742...7,289,309
|
|
G |
Cpt1c |
carnitine palmitoyltransferase 1c |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CPT1C mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:95,442,814...95,457,347
|
|
G |
Cr2 |
complement C3d receptor 2 |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of CR2 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CR2 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr13:109,207,034...109,244,980
|
|
G |
Crb2 |
crumbs cell polarity complex component 2 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of CRB2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:21,542,138...21,564,876
|
|
G |
Crebzf |
CREB/ATF bZIP transcription factor |
affects expression |
ISO |
benz(a)anthracene affects the expression of CREBZF mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:153,829,544...153,836,073
|
|
G |
Crip3 |
cysteine-rich protein 3 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of CRIP3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 9:14,554,450...14,557,344
|
|
G |
Crk |
CRK proto-oncogene, adaptor protein |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of CRK mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CRK mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr10:61,028,736...61,054,971
|
|
G |
Cry2 |
cryptochrome circadian regulator 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CRY2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:98,830,479...98,860,437
|
|
G |
Csf2ra |
colony stimulating factor 2 receptor subunit alpha |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of CSF2RA mRNA |
CTD |
PMID:26377693 |
|
NCBI chr14:113,219...118,808
|
|
G |
Csf2rb |
colony stimulating factor 2 receptor subunit beta |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CSF2RB2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 7:109,876,919...109,901,589
|
|
G |
Cst8 |
cystatin 8 |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of CST8 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CST8 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 3:136,244,586...136,255,412
|
|
G |
Cstf3 |
cleavage stimulation factor subunit 3 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of CSTF3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:90,966,415...91,037,669
|
|
G |
Cul9 |
cullin 9 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CUL9 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 9:14,435,948...14,479,552
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of CXCL12 mRNA bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [benz(a)anthracene results in increased expression of CXCL12 mRNA]]; Tetradecanoylphorbol Acetate inhibits the reaction [benz(a)anthracene results in increased expression of CXCL12 mRNA] |
CTD |
PMID:22643241 |
|
NCBI chr 4:152,060,781...152,073,628
|
|
G |
Cxcl13 |
C-X-C motif chemokine ligand 13 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CXCL13 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr14:13,608,894...13,613,965
|
|
G |
Cxcr5 |
C-X-C motif chemokine receptor 5 |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of CXCR5 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CXCR5 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 8:53,738,878...53,756,813
|
|
G |
Cxcr6 |
C-X-C motif chemokine receptor 6 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CXCR6 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 8:123,434,417...123,439,568
|
|
G |
Cyld |
CYLD lysine 63 deubiquitinase |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CYLD mRNA |
CTD |
PMID:27858113 |
|
NCBI chr19:34,487,491...34,547,311
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
increases expression decreases expression multiple interactions |
EXP ISO |
benz(a)anthracene results in increased expression of CYP17A1 mRNA benz(a)anthracene results in decreased expression of CYP17A1 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:23358148 PMID:26377693 PMID:27858113 |
|
NCBI chr 1:245,535,462...245,543,148
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases metabolic processing increases expression increases activity |
ISO EXP |
[benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with Benzo(a)pyrene co-treated with chrysene] results in increased expression of CYP1A1 mRNA; [benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with Benzo(a)pyrene co-treated with chrysene] results in increased expression of CYP1A1 protein; [CYP1A1 protein co-treated with Trichloroepoxypropane] results in increased metabolism of benz(a)anthracene; AHR protein promotes the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; baicalein inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]; benz(a)anthracene promotes the reaction [AHR protein results in increased expression of CYP1A1 mRNA]; Cadmium Chloride inhibits the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; CYP1A1 gene polymorphism affects the reaction [benz(a)anthracene results in increased expression of CYP1A1 protein]; EPHX1 protein promotes the reaction [CYP1A1 protein results in increased metabolism of benz(a)anthracene]; lead nitrate inhibits the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; Mercuric Chloride inhibits the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; sodium arsenite inhibits the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA] [andrographolide co-treated with benz(a)anthracene] results in increased expression of CYP1A1 mRNA; [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CYP1A1 mRNA; [CYP1A1 protein co-treated with Trichloroepoxypropane] results in increased metabolism of benz(a)anthracene; [fluoranthene co-treated with pyrene co-treated with benz(a)anthracene co-treated with chrysene co-treated with benzo(b)fluoranthene co-treated with benzo(k)fluoranthene co-treated with Benzo(a)pyrene] results in increased expression of CYP1A1 mRNA; Dactinomycin promotes the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]; EPHX1 protein promotes the reaction [CYP1A1 protein results in increased metabolism of benz(a)anthracene]; resveratrol inhibits the reaction [[andrographolide co-treated with benz(a)anthracene] results in increased expression of CYP1A1 mRNA] benz(a)anthracene results in increased expression of CYP1A1 mRNA; benz(a)anthracene results in increased expression of CYP1A1 protein 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]; 1-(5-isoquinolinylsulfonyl)-3-methylpiperazine inhibits the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; [chrysene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; [chrysene co-treated with benz(a)anthracene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] results in increased expression of CYP1A1 mRNA; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene] results in increased expression of CYP1A1 mRNA; [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 protein]; AHR affects the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]; Dexamethasone promotes the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; Dexamethasone promotes the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]; Mifepristone inhibits the reaction [Dexamethasone promotes the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]]; NR3C1 protein promotes the reaction [Dexamethasone promotes the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]]; Staurosporine inhibits the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein] |
CTD |
PMID:1358564 PMID:1521541 PMID:1846074 PMID:1934297 PMID:2052000 PMID:2154339 PMID:2154949 PMID:2208584 PMID:2714275 PMID:2916850 PMID:7587946 PMID:7663528 PMID:7750161 PMID:7980650 PMID:8149487 PMID:8674863 PMID:8812189 PMID:8961944 PMID:9013560 PMID:9452186 PMID:9592188 PMID:9783729 PMID:10190573 PMID:11162773 PMID:11377097 PMID:11408366 PMID:11454723 PMID:12117779 PMID:12224597 PMID:12520072 PMID:17141280 PMID:17156822 PMID:17253728 PMID:17825862 PMID:18205319 PMID:21384493 PMID:21781905 PMID:22120587 PMID:22236718 PMID:22643241 PMID:23358148 PMID:26377693 PMID:26621329 PMID:27196671 PMID:27858113 PMID:30991879 PMID:32890658 PMID:37189300 PMID:38237855 More...
|
|
NCBI chr 8:66,991,940...66,998,014
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions increases expression decreases activity affects response to substance |
ISO EXP |
[CYP1A2 protein co-treated with Trichloroepoxypropane] results in increased metabolism of benz(a)anthracene; EPHX1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of benz(a)anthracene] [andrographolide co-treated with benz(a)anthracene] results in increased expression of CYP1A2 mRNA; [CYP1A2 protein co-treated with Trichloroepoxypropane] results in increased metabolism of benz(a)anthracene; [fluoranthene co-treated with pyrene co-treated with benz(a)anthracene co-treated with chrysene co-treated with benzo(b)fluoranthene co-treated with benzo(k)fluoranthene co-treated with Benzo(a)pyrene] results in increased expression of CYP1A2 mRNA; EPHX1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of benz(a)anthracene] benz(a)anthracene results in increased expression of CYP1A2 mRNA benz(a)anthracene results in decreased activity of CYP1A2 protein CYP1A2 protein affects the susceptibility to benz(a)anthracene [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] results in increased expression of CYP1A2 mRNA; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene] results in increased expression of CYP1A2 mRNA |
CTD |
PMID:7750161 PMID:8961944 PMID:9783729 PMID:11162773 PMID:17253728 PMID:17825862 PMID:21384493 PMID:23358148 PMID:37189300 More...
|
|
NCBI chr 8:66,971,261...66,978,149
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions increases stability increases expression |
ISO EXP |
[benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with Benzo(a)pyrene co-treated with chrysene] results in increased expression of CYP1B1 mRNA; [benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with Benzo(a)pyrene co-treated with chrysene] results in increased expression of CYP1B1 protein; [benz(a)anthracene co-treated with TNF protein] results in increased expression of CYP1B1 mRNA; AHR protein affects the reaction [benz(a)anthracene results in increased expression of CYP1B1 mRNA]; baicalein inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 mRNA] [andrographolide co-treated with benz(a)anthracene] results in increased expression of CYP1B1 mRNA; [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CYP1B1 mRNA; benz(a)anthracene promotes the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]; Dehydroepiandrosterone inhibits the reaction [benz(a)anthracene promotes the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]]; Dehydroepiandrosterone inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 mRNA] benz(a)anthracene results in increased stability of CYP1B1 protein [benz(a)anthracene co-treated with benzo(b)fluoranthene] promotes the reaction [chrysene promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]]; [chrysene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]; [chrysene co-treated with benz(a)anthracene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] results in increased expression of CYP1B1 mRNA; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene] results in increased expression of CYP1B1 mRNA; [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein]; Hydrocortisone inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 mRNA]; Hydrocortisone inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein]; Progesterone inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein] benz(a)anthracene results in increased expression of CYP1B1 mRNA; benz(a)anthracene results in increased expression of CYP1B1 protein |
CTD |
PMID:7505439 PMID:8022408 PMID:8674863 PMID:9783729 PMID:10037446 PMID:10497882 PMID:12117779 PMID:12224597 PMID:12520072 PMID:17253728 PMID:17825862 PMID:18205319 PMID:19358281 PMID:21384493 PMID:22236718 PMID:23358148 PMID:23396138 PMID:26377693 PMID:27196671 PMID:27858113 PMID:32890658 PMID:37189300 PMID:38237855 More...
|
|
NCBI chr 6:21,093,927...21,103,091
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of CYP2E1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:205,269,967...205,280,365
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of CYP2J9 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:116,295,691...116,323,219
|
|
G |
Cys1 |
cystin 1 |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of CYS1 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CYS1 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 6:41,300,836...41,318,071
|
|
G |
Dact2 |
dishevelled-binding antagonist of beta-catenin 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of DACT2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:63,854,182...63,864,153
|
|
G |
Dancr |
differentiation antagonizing non-protein coding RNA |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of DANCR mRNA |
CTD |
PMID:26377693 |
|
NCBI chr14:34,481,052...34,482,032
|
|
G |
Dars1 |
aspartyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DARS1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr13:39,857,936...39,913,055
|
|
G |
Dbp |
D-box binding PAR bZIP transcription factor |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of DBP mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DBP mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 1:96,175,796...96,180,745
|
|
G |
Dcaf12l2 |
DDB1 and CUL4 associated factor 12-like 2 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of DCAF12L2 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DCAF12L2 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr X:123,293,761...123,296,550
|
|
G |
Dcaf4 |
DDB1 and CUL4 associated factor 4 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DCAF4 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 6:103,154,847...103,180,992
|
|
G |
Dcc |
DCC netrin 1 receptor |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DCC mRNA |
CTD |
PMID:27858113 |
|
NCBI chr18:64,868,987...65,972,783
|
|
G |
Dcdc2 |
doublecortin domain containing 2 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of DCDC2A mRNA |
CTD |
PMID:26377693 |
|
NCBI chr17:40,274,009...40,459,757
|
|
G |
Dcn |
decorin |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DCN mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 7:34,167,973...34,208,004
|
|
G |
Ddah1 |
dimethylarginine dimethylaminohydrolase 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDAH1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 2:234,667,499...234,800,322
|
|
G |
Ddb2 |
damage specific DNA binding protein 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of DDB2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:77,185,114...77,207,650
|
|
G |
Ddc |
dopa decarboxylase |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDC mRNA |
CTD |
PMID:27858113 |
|
NCBI chr14:86,378,685...86,469,189
|
|
G |
Ddias |
DNA damage-induced apoptosis suppressor |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDIAS mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:146,906,150...146,930,462
|
|
G |
Ddit4l |
DNA-damage-inducible transcript 4-like |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDIT4L mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 2:226,128,273...226,131,044
|
|
G |
Ddx17 |
DEAD-box helicase 17 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of DDX17 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 7:111,091,127...111,109,353
|
|
G |
Ddx25 |
DEAD-box helicase 25 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DDX25 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 8:33,894,224...33,910,377
|
|
G |
Ddx5 |
DEAD-box helicase 5 |
affects expression multiple interactions |
ISO |
benz(a)anthracene affects the expression of DDX5 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DDX5 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr10:91,723,508...91,732,210
|
|
G |
Dennd1c |
DENN domain containing 1C |
increases expression |
ISO |
benz(a)anthracene results in increased expression of DENND1C mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 9:1,991,035...2,003,330
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DGAT2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:153,454,078...153,484,432
|
|
G |
Dgkq |
diacylglycerol kinase, theta |
increases expression |
ISO |
benz(a)anthracene results in increased expression of DGKQ mRNA |
CTD |
PMID:26377693 |
|
NCBI chr14:1,203,380...1,217,536
|
|
G |
Dhrs7b |
dehydrogenase/reductase 7B |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of DHRS7B mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:45,504,344...45,537,094
|
|
G |
Dhx34 |
DExH-box helicase 34 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of DHX34 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:76,880,867...76,905,148
|
|
G |
Dhx35 |
DEAH-box helicase 35 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of DHX35 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:147,450,178...147,507,473
|
|
G |
Dhx58 |
DEXH-box helicase 58 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of DHX58 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:85,620,352...85,631,776
|
|
G |
Diaph1 |
diaphanous-related formin 1 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of DIAP1 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DIAP1 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr18:29,669,659...29,769,070
|
|
G |
Dido1 |
death inducer-obliterator 1 |
multiple interactions affects expression |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DIDO1 mRNA benz(a)anthracene affects the expression of DIDO1 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 3:188,150,100...188,203,445
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of DIO2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 6:115,396,308...115,410,594
|
|
G |
Dipk1b |
divergent protein kinase domain 1B |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DIPK1B mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 3:29,852,710...29,862,248
|
|
G |
Diras2 |
DIRAS family GTPase 2 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of DIRAS2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr17:12,730,040...12,761,511
|
|
G |
Dmp1 |
dentin matrix acidic phosphoprotein 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of DMP1 mRNA |
CTD |
PMID:19000923 |
|
NCBI chr14:5,833,111...5,867,154
|
|
G |
Dnaaf4 |
dynein axonemal assembly factor 4 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of DNAAF4 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:82,577,044...82,601,653
|
|
G |
Dnah10 |
dynein, axonemal, heavy chain 10 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of DNAH10 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr12:37,484,444...37,607,810
|
|
G |
Dnah2 |
dynein, axonemal, heavy chain 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of DNAH2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:54,142,648...54,268,901
|
|
G |
Dnah8 |
dynein, axonemal, heavy chain 8 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of DNAH8 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr20:8,692,939...8,946,780
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of DNAJA1 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DNAJA1 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 5:55,842,414...55,853,326
|
|
G |
Dnaja4 |
DnaJ heat shock protein family (Hsp40) member A4 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of DNAJA4 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:55,085,246...55,102,715
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of DNAJB1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr19:41,427,453...41,431,141
|
|
G |
Dnajb4 |
DnaJ heat shock protein family (Hsp40) member B4 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DNAJB4 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 2:243,790,296...243,819,042
|
|
G |
Dnajc21 |
DnaJ heat shock protein family (Hsp40) member C21 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of DNAJC21 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 2:59,419,507...59,446,746
|
|
G |
Dnajc8 |
DnaJ heat shock protein family (Hsp40) member C8 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DNAJC8 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 5:150,029,064...150,047,115
|
|
G |
Dock6 |
dedicator of cytokinesis 6 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of DOCK6 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:20,342,430...20,394,660
|
|
G |
Dok3 |
docking protein 3 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of DOK3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr17:9,109,633...9,115,188
|
|
G |
Dot1l |
DOT1 like histone lysine methyltransferase |
increases expression |
ISO |
benz(a)anthracene results in increased expression of DOT1L mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 7:8,918,764...8,959,474
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
ISO |
[Particulate Matter results in increased abundance of benz(a)anthracene] which results in decreased expression of DRD1 mRNA |
CTD |
PMID:38739786 |
|
NCBI chr17:10,545,488...10,550,029
|
|
G |
Dst |
dystonin |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of DST mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 9:36,135,657...36,529,617
|
|
G |
Dtl |
denticleless E3 ubiquitin protein ligase homolog |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DTL mRNA |
CTD |
PMID:27858113 |
|
NCBI chr13:105,646,908...105,685,921
|
|
G |
Dtx4 |
deltex E3 ubiquitin ligase 4 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DTX4 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:209,457,719...209,545,163
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of DUSP2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:135,009,636...135,011,821
|
|
G |
Dvl3 |
dishevelled segment polarity protein 3 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of DVL3 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DVL3 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr11:80,365,446...80,382,641
|
|
G |
Dync2i1 |
dynein 2 intermediate chain 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of DYNC2I1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 6:137,133,418...137,189,937
|
|
G |
Dzip1 |
DAZ interacting zinc finger protein 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DZIP1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr15:95,956,329...96,009,994
|
|
G |
Echdc2 |
enoyl CoA hydratase domain containing 2 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of ECHDC2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:122,915,874...122,934,860
|
|
G |
Ecm1 |
extracellular matrix protein 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ECM1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 2:183,287,491...183,292,729
|
|
G |
Edn1 |
endothelin 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of EDN1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr17:22,660,799...22,666,687
|
|
G |
Ednrb |
endothelin receptor type B |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EDNRB mRNA |
CTD |
PMID:27858113 |
|
NCBI chr15:87,055,490...87,086,765
|
|
G |
Eeig1 |
estrogen-induced osteoclastogenesis regulator 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of EEIG1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:15,822,441...15,854,651
|
|
G |
Efcab12 |
EF-hand calcium binding domain 12 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of EFCAB12 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:148,869,381...148,892,922
|
|
G |
Efhb |
EF hand domain family, member B |
increases expression |
ISO |
benz(a)anthracene results in increased expression of EFHB mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 9:6,608,791...6,680,104
|
|
G |
Efnb1 |
ephrin B1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EFNB1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr X:64,257,351...64,270,158
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
AHR protein affects the reaction [benz(a)anthracene inhibits the reaction [EGF protein binds to EGFR protein]]; benz(a)anthracene inhibits the reaction [EGF protein binds to EGFR protein] |
CTD |
PMID:6309801 |
|
NCBI chr 2:220,893,660...220,976,331
|
|
G |
Egfl7 |
EGF-like-domain, multiple 7 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of EGFL7 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:29,802,481...29,814,966
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
AHR protein affects the reaction [benz(a)anthracene inhibits the reaction [EGF protein binds to EGFR protein]]; benz(a)anthracene inhibits the reaction [EGF protein binds to EGFR protein] |
CTD |
PMID:6309801 |
|
NCBI chr14:95,378,626...95,551,358
|
|
G |
Ehbp1 |
EH domain binding protein 1 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of EHBP1 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EHBP1 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr14:96,093,327...96,380,502
|
|
G |
Ehd1 |
EH-domain containing 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EHD1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:203,579,850...203,602,226
|
|
G |
Ehd4 |
EH-domain containing 4 |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of EHD4 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EHD4 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 3:107,058,191...107,121,985
|
|
G |
Eif2ak4 |
eukaryotic translation initiation factor 2 alpha kinase 4 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of EIF2AK4 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:125,810,207...125,895,574
|
|
G |
Eif2s3y |
eukaryotic translation initiation factor 2, subunit 3, structural gene Y-linked |
increases expression |
ISO |
benz(a)anthracene results in increased expression of EIF2S3Y mRNA |
CTD |
PMID:26377693 |
|
NCBI chr Y:869,654...889,341
|
|
G |
Eif3j |
eukaryotic translation initiation factor 3, subunit J |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of EIF3J mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:108,985,103...109,007,341
|
|
G |
Elovl1 |
ELOVL fatty acid elongase 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ELOVL1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:131,961,478...131,965,961
|
|
G |
Emcn |
endomucin |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EMCN mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 2:228,564,445...228,644,370
|
|
G |
Eml1 |
EMAP like 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EML1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 6:127,283,968...127,457,246
|
|
G |
Enpp3 |
ectonucleotide pyrophosphatase/phosphodiesterase 3 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of ENPP3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:20,563,700...20,635,044
|
|
G |
Epb41 |
erythrocyte membrane protein band 4.1 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of EPB41 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EPB41 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 5:144,110,010...144,264,037
|
|
G |
Epha1 |
Eph receptor A1 |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of EPHA1 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EPHA1 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 4:72,213,022...72,227,543
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
multiple interactions increases expression |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EPHX1 mRNA; EPHX1 protein promotes the reaction [CYP1A1 protein results in increased metabolism of benz(a)anthracene]; EPHX1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of benz(a)anthracene] benz(a)anthracene results in increased expression of EPHX1 protein |
CTD |
PMID:2208584 PMID:8961944 PMID:27858113 |
|
NCBI chr13:95,246,079...95,275,852
|
|
G |
Epm2aip1 |
EPM2A interacting protein 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of EPM2AIP1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:120,112,265...120,119,613
|
|
G |
Epor |
erythropoietin receptor |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of EPOR mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EPOR mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 8:28,765,738...28,770,371
|
|
G |
Eps8l1 |
EPS8 signaling adaptor L1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of EPS8L1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:69,343,202...69,359,778
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of ERBB2 mRNA |
CTD |
PMID:21635667 |
|
NCBI chr10:83,907,491...83,931,365
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ERCC1 mRNA |
CTD |
PMID:22236718 |
|
NCBI chr 1:78,971,310...79,007,963
|
|
G |
Ermn |
ermin |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ERMN mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 3:42,628,160...42,633,816
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases expression increases phosphorylation decreases expression increases activity |
ISO EXP |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with chrysene] results in increased expression of ESR1 mRNA; benz(a)anthracene promotes the reaction [Estradiol results in increased activity of ESR1 protein]; fulvestrant inhibits the reaction [benz(a)anthracene promotes the reaction [Estradiol results in increased activity of ESR1 protein]] benz(a)anthracene results in increased expression of ESR1 mRNA benz(a)anthracene results in increased phosphorylation of ESR1 protein benz(a)anthracene results in decreased expression of ESR1 protein benz(a)anthracene results in increased activity of ESR1 protein |
CTD |
PMID:11922773 PMID:12441364 PMID:18634860 PMID:21783948 PMID:25012808 |
|
NCBI chr 1:43,511,685...43,904,454
|
|
G |
Etfbkmt |
electron transfer flavoprotein subunit beta lysine methyltransferase |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ETFBKMT mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:182,140,492...182,204,635
|
|
G |
Ets1 |
ETS proto-oncogene 1, transcription factor |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [benz(a)anthracene results in increased expression of ETS1 mRNA]; SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of ETS1 mRNA] |
CTD |
PMID:21635667 |
|
NCBI chr 8:39,303,936...39,426,022
|
|
G |
Etv5 |
ETS variant transcription factor 5 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ETV5 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr11:78,608,618...78,666,221
|
|
G |
Eva1a |
eva-1 homolog A, regulator of programmed cell death |
increases expression |
ISO |
benz(a)anthracene results in increased expression of EVA1A mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:114,593,773...114,643,011
|
|
G |
Ewsr1 |
EWS RNA-binding protein 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of EWSR1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr14:79,965,365...79,994,108
|
|
G |
Exoc3l1 |
exocyst complex component 3-like 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of EXOC3L mRNA |
CTD |
PMID:26377693 |
|
NCBI chr19:33,166,836...33,174,371
|
|
G |
Exoc4 |
exocyst complex component 4 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EXOC4 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 4:62,774,896...63,551,541
|
|
G |
Exoc6b |
exocyst complex component 6B |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of EXOC6B mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:117,094,741...117,550,221
|
|
G |
Exosc7 |
exosome component 7 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of EXOSC7 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:122,773,607...122,798,943
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of FABP1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:104,744,302...104,753,119
|
|
G |
Fabp12 |
fatty acid binding protein 12 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of FABP12 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 2:91,539,568...91,554,999
|
|
G |
Fam107a |
family with sequence similarity 107, member A |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FAM107A mRNA |
CTD |
PMID:27858113 |
|
NCBI chr15:19,038,726...19,060,644
|
|
G |
Fam110d |
family with sequence similarity 110, member D |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM110D mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 5:146,471,048...146,474,019
|
|
G |
Fam133b |
family with sequence similarity 133, member B |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM133B mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 4:30,589,646...30,616,291
|
|
G |
Fam135a |
family with sequence similarity 135, member A |
increases expression |
ISO |
benz(a)anthracene results in increased expression of FAM135A mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 9:26,420,116...26,500,803
|
|
G |
Fam13c |
family with sequence similarity 13, member C |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM13C mRNA |
CTD |
PMID:27858113 |
|
NCBI chr20:18,064,706...18,186,888
|
|
G |
Fam193b |
family with sequence similarity 193, member B |
affects expression |
ISO |
benz(a)anthracene affects the expression of FAM193B mRNA |
CTD |
PMID:26377693 |
|
NCBI chr17:9,066,818...9,099,511
|
|
G |
Fam20b |
FAM20B, glycosaminoglycan xylosylkinase |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM20B mRNA |
CTD |
PMID:27858113 |
|
NCBI chr13:68,801,663...68,839,979
|
|
G |
Fam76b |
family with sequence similarity 76, member B |
increases expression |
ISO |
benz(a)anthracene results in increased expression of FAM76B mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:18,971,357...18,993,442
|
|
G |
Farp1 |
FERM, ARH/RhoGEF and pleckstrin domain protein 1 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of FARP1 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FARP1 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr15:98,124,304...98,363,299
|
|
G |
Fastk |
Fas-activated serine/threonine kinase |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of FASTK mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FASTK mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 4:11,624,697...11,628,769
|
|
G |
Fbxl12 |
F-box and leucine-rich repeat protein 12 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of FBXL12 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:19,175,864...19,183,373
|
|
G |
Fbxl13 |
F-box and leucine-rich repeat protein 13 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of FBXL13 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:13,414,880...13,607,079
|
|
G |
Fbxl20 |
F-box and leucine-rich repeat protein 20 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of FBXL20 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:83,577,038...83,640,022
|
|
G |
Fcer2 |
Fc epsilon receptor II |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of FCER2A mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FCER2A mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr12:1,742,809...1,754,476
|
|
G |
Fcmr |
Fc mu receptor |
increases expression |
ISO |
benz(a)anthracene results in increased expression of FCMR mRNA |
CTD |
PMID:26377693 |
|
NCBI chr13:42,337,363...42,351,706
|
|
G |
Fcrla |
Fc receptor-like A |
increases expression |
ISO |
benz(a)anthracene results in increased expression of FCRLA mRNA |
CTD |
PMID:26377693 |
|
NCBI chr13:83,160,453...83,170,170
|
|
G |
Fgd6 |
FYVE, RhoGEF and PH domain containing 6 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of FGD6 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 7:28,597,609...28,712,908
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of FGF7 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:133,734,557...133,786,678
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of FGF9 mRNA |
CTD |
PMID:19358281 |
|
NCBI chr15:32,208,993...32,254,952
|
|
G |
Fgfr1op2 |
FGFR1 oncogene partner 2 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of FGFR1OP2 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FGFR1OP2 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 4:179,491,602...179,512,630
|
|
G |
Fgg |
fibrinogen gamma chain |
increases expression |
ISO |
benz(a)anthracene results in increased expression of FGG mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 2:168,354,880...168,362,325
|
|
G |
Fibin |
fin bud initiation factor homolog |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FIBIN mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 3:96,942,405...96,944,676
|
|
G |
Fig4 |
FIG4 phosphoinositide 5-phosphatase |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FIG4 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr20:44,600,603...44,724,047
|
|
G |
Fignl1 |
fidgetin-like 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FIGNL1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr14:86,368,670...86,381,728
|
|
G |
Fkbp1a |
FKBP prolyl isomerase 1A |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of FKBP1A mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FKBP1A mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 3:160,500,748...160,520,492
|
|
G |
Flii |
FLII, actin remodeling protein |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FLII mRNA |
CTD |
PMID:27858113 |
|
NCBI chr10:45,893,566...45,907,547
|
|
G |
Flt3lg |
Fms related receptor tyrosine kinase 3 ligand |
increases expression |
ISO |
benz(a)anthracene results in increased expression of FLT3L mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:104,751,518...104,756,925
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FMO1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr13:75,182,184...75,214,439
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FMR1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr X:147,240,239...147,278,057
|
|
G |
Fn3k |
fructosamine 3 kinase |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of FN3K mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:107,198,566...107,214,176
|
|
G |
Fnbp4 |
formin binding protein 4 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of FNBP4 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:97,188,852...97,218,916
|
|
G |
Fndc1 |
fibronectin type III domain containing 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FNDC1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:47,281,839...47,364,247
|
|
G |
Folr2 |
folate receptor beta |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of FOLR2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:165,612,047...165,630,382
|
|
G |
Foxa2 |
forkhead box A2 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of FOXA2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:135,470,123...135,474,326
|
|
G |
Foxf1 |
forkhead box F1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FOXF1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr19:49,153,949...49,157,741
|
|
G |
Foxq1 |
forkhead box Q1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of FOXQ1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr17:32,912,744...32,915,377
|
|
G |
Foxs1 |
forkhead box S1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FOXS1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 3:141,397,012...141,398,296
|
|
G |
Fras1 |
Fraser extracellular matrix complex subunit 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of FRAS1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr14:12,791,407...13,200,862
|
|
G |
Frem1 |
Fras1 related extracellular matrix 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of FREM1 mRNA |
CTD |
PMID:21635667 |
|
NCBI chr 5:97,321,266...97,469,523
|
|
G |
Frg1 |
FSHD region gene 1 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of FRG1 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FRG1 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr16:50,925,783...50,946,661
|
|
G |
Frmd4b |
FERM domain containing 4B |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FRMD4B mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 4:131,452,361...131,778,734
|
|
G |
Fscn3 |
fascin actin-bundling protein 3 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FSCN3 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 4:57,042,797...57,052,224
|
|
G |
Fus |
Fus RNA binding protein |
increases expression |
ISO |
benz(a)anthracene results in increased expression of FUS mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:182,576,479...182,590,417
|
|
G |
Fzd4 |
frizzled class receptor 4 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of FZD4 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:143,279,934...143,288,799
|
|
G |
Fzd6 |
frizzled class receptor 6 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of FZD6 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 7:70,055,012...70,086,781
|
|
G |
Gabbr1 |
gamma-aminobutyric acid type B receptor subunit 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of GABBR1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr20:1,469,779...1,499,352
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
ISO |
benz(a)anthracene metabolite results in increased expression of GADD45A protein; benz(a)anthracene results in increased expression of GADD45A mRNA |
CTD |
PMID:22236718 PMID:31051210 |
|
NCBI chr 4:97,484,497...97,486,799
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of GADD45G mRNA |
CTD |
PMID:26377693 |
|
NCBI chr17:13,528,606...13,530,351
|
|
G |
Galnt15 |
polypeptide N-acetylgalactosaminyltransferase 15 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of GALNT15 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr16:7,227,232...7,267,002
|
|
G |
Gas1 |
growth arrest-specific 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of GAS1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr17:4,487,716...4,490,701
|
|
G |
Gas5 |
growth arrest specific 5 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of GAS5 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr13:73,303,611...73,306,932
|
|
G |
Gas6 |
growth arrest specific 6 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GAS6 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr16:82,747,676...82,778,090
|
|
G |
Gask1b |
golgi associated kinase 1B |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GASK1B mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 2:165,047,689...165,112,479
|
|
G |
Gata2 |
GATA binding protein 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GATA2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 4:120,654,205...120,667,763
|
|
G |
Gbe1 |
1,4-alpha-glucan branching enzyme 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of GBE1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr11:8,734,806...9,000,226
|
|
G |
Gbp6 |
guanylate binding protein family member 6 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of GBP6 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr14:5,034,999...5,062,023
|
|
G |
Gcc2 |
GRIP and coiled-coil domain containing 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of GCC2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr20:26,247,394...26,293,613
|
|
G |
Gcgr |
glucagon receptor |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GCGR mRNA |
CTD |
PMID:27858113 |
|
NCBI chr10:106,306,803...106,314,970
|
|
G |
Gcm1 |
glial cells missing transcription factor 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GCM1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 8:78,925,687...78,938,924
|
|
G |
Gdf10 |
growth differentiation factor 10 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of GDF10 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr16:9,237,182...9,250,537
|
|
G |
Gdf15 |
growth differentiation factor 15 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GDF15 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr16:18,838,436...18,842,022
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
increases expression |
ISO |
benz(a)anthracene results in increased expression of GDNF mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 2:58,621,327...58,647,242
|
|
G |
Gfra4 |
GDNF family receptor alpha 4 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of GFRA4 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GFRA4 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 3:118,254,937...118,262,252
|
|
G |
Gja5 |
gap junction protein, alpha 5 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of GJA5 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 2:187,291,227...187,310,770
|
|
G |
Gjb1 |
gap junction protein, beta 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GJB1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr X:66,501,848...66,509,783
|
|
G |
Gjc2 |
gap junction protein, gamma 2 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of GJC2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:43,962,642...43,971,358
|
|
G |
Gkn2 |
gastrokine 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of GKN2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:119,778,326...119,824,366
|
|
G |
Glis2 |
GLIS family zinc finger 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GLIS2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr10:11,457,594...11,484,948
|
|
G |
Glt8d1 |
glycosyltransferase 8 domain containing 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of GLT8D1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr16:6,192,269...6,207,227
|
|
G |
Glt8d2 |
glycosyltransferase 8 domain containing 2 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of GLT8D2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 7:21,029,534...21,081,081
|
|
G |
Gmnn |
geminin, DNA replication inhibitor |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of GMNN mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GMNN mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr17:40,729,760...40,738,077
|
|
G |
Gon4l |
gon-4 like |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of GON4L mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 2:176,531,274...176,604,446
|
|
G |
Gpcpd1 |
glycerophosphocholine phosphodiesterase 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of GPCPD1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:119,787,681...119,832,550
|
|
G |
Gpd1 |
glycerol-3-phosphate dehydrogenase 1 |
multiple interactions increases activity |
ISO |
benz(a)anthracene inhibits the reaction [Dehydroepiandrosterone results in increased activity of GPD1 protein] benz(a)anthracene results in increased activity of GPD1 protein |
CTD |
PMID:10497882 |
|
NCBI chr 7:130,842,526...130,851,530
|
|
G |
Gpihbp1 |
glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GPIHBP1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 7:107,285,584...107,288,702
|
|
G |
Gpr174 |
G protein-coupled receptor 174 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of GPR174 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr X:72,355,452...72,396,146
|
|
G |
Gpr4 |
G protein-coupled receptor 4 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GPR4 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:78,865,376...78,877,126
|
|
G |
Gprin3 |
GPRIN family member 3 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of GPRIN3 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GPRIN3 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 4:88,572,062...88,657,369
|
|
G |
Gpx6 |
glutathione peroxidase 6 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of GPX6 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr17:43,408,472...43,416,091
|
|
G |
Gramd1a |
GRAM domain containing 1A |
increases expression |
ISO |
benz(a)anthracene results in increased expression of GRAMD1A mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:86,367,001...86,393,348
|
|
G |
Gramd1c |
GRAM domain containing 1C |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of GRAMD1C mRNA |
CTD |
PMID:26377693 |
|
NCBI chr11:56,633,229...56,718,570
|
|
G |
Grb10 |
growth factor receptor bound protein 10 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of GRB10 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GRB10 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr14:90,708,653...90,816,399
|
|
G |
Greb1 |
growth regulating estrogen receptor binding 1 |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of GREB1 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GREB1 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 6:39,440,522...39,562,364
|
|
G |
Grifin |
galectin-related inter-fiber protein |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GRIFIN mRNA |
CTD |
PMID:27858113 |
|
NCBI chr12:14,080,170...14,082,892
|
|
G |
Grk3 |
G protein-coupled receptor kinase 3 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of GRK3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr12:49,285,228...49,395,803
|
|
G |
Grp |
gastrin releasing peptide |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GRP mRNA |
CTD |
PMID:27858113 |
|
NCBI chr18:59,388,679...59,402,061
|
|
G |
Gsap |
gamma-secretase activating protein |
increases expression |
ISO |
benz(a)anthracene results in increased expression of GSAP mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:13,813,046...13,907,875
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of GSTA1 mRNA |
CTD |
PMID:32890658 |
|
NCBI chr 9:23,703,476...23,720,121
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
multiple interactions increases activity increases expression |
EXP |
1-(5-isoquinolinylsulfonyl)-3-methylpiperazine inhibits the reaction [benz(a)anthracene results in increased activity of GSTA2 protein]; Dexamethasone promotes the reaction [benz(a)anthracene results in increased activity of GSTA2 protein]; Dexamethasone promotes the reaction [benz(a)anthracene results in increased expression of GSTA2 mRNA]; Staurosporine inhibits the reaction [benz(a)anthracene results in increased activity of GSTA2 protein] |
CTD |
PMID:7587946 |
|
NCBI chr 8:79,184,535...79,196,827
|
|
G |
Gtf3c2 |
general transcription factor IIIC subunit 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of GTF3C2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 6:25,196,439...25,221,338
|
|
G |
Gtpbp2 |
GTP binding protein 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of GTPBP2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 9:14,813,964...14,823,419
|
|
G |
Gzma |
granzyme A |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GZMA mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 2:44,740,569...44,752,502
|
|
G |
H1f2 |
H1.2 linker histone, cluster member |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of H1F2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr17:41,818,962...41,820,453
|
|
G |
H1f4 |
H1.4 linker histone, cluster member |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of H1F4 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr17:41,914,425...41,915,206
|
|
G |
H2ax |
H2A.X variant histone |
increases expression |
ISO |
benz(a)anthracene metabolite results in increased expression of H2AX protein |
CTD |
PMID:31051210 |
|
NCBI chr 8:53,568,718...53,570,072
|
|
G |
Haghl |
hydroxyacylglutathione hydrolase-like |
increases expression |
ISO |
benz(a)anthracene results in increased expression of HAGHL mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:14,804,957...14,809,495
|
|
G |
Haus4 |
HAUS augmin-like complex, subunit 4 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of HAUS4 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr15:27,994,530...28,006,147
|
|
G |
Haus5 |
HAUS augmin-like complex, subunit 5 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of HAUS5 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:85,912,371...85,924,327
|
|
G |
Hck |
HCK proto-oncogene, Src family tyrosine kinase |
increases expression |
ISO |
benz(a)anthracene results in increased expression of HCK mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:162,031,833...162,074,933
|
|
G |
Hdac10 |
histone deacetylase 10 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of HDAC10 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 7:120,199,126...120,205,850
|
|
G |
Heatr1 |
HEAT repeat containing 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HEATR1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr17:58,053,288...58,093,895
|
|
G |
Helz2 |
helicase with zinc finger 2 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of HELZ2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:168,338,813...168,353,219
|
|
G |
Herc1 |
HECT and RLD domain containing E3 ubiquitin protein ligase family member 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of HERC1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:75,796,347...75,965,347
|
|
G |
Herc3 |
HECT and RLD domain containing E3 ubiquitin protein ligase 3 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of HERC3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:87,952,202...88,042,492
|
|
G |
Hes2 |
hes family bHLH transcription factor 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of HES2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:167,947,948...167,964,660
|
|
G |
Hic1 |
HIC ZBTB transcriptional repressor 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HIC1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr10:60,512,855...60,517,812
|
|
G |
Hilpda |
hypoxia inducible lipid droplet-associated |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HILPDA mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 4:58,836,463...58,839,423
|
|
G |
Hkdc1 |
hexokinase domain containing 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of HKDC1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr20:30,878,037...30,917,044
|
|
G |
Hlf |
HLF transcription factor, PAR bZIP family member |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of HLF mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HLF mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr10:75,651,320...75,708,979
|
|
G |
Hm13 |
histocompatibility minor 13 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of H13 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 3:141,145,792...141,183,557
|
|
G |
Hmcn1 |
hemicentin 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HMCN1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr13:65,165,532...65,634,681
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HMGB1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr12:11,009,236...11,015,941
|
|
G |
Hmgn2 |
high mobility group nucleosomal binding domain 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of HMGN2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:146,192,126...146,195,580
|
|
G |
Hmgn5 |
high mobility group nucleosome binding domain 5 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of HMGN5 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HMGN5 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr X:78,161,439...78,170,613
|
|
G |
Hnmt |
histamine N-methyltransferase |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of HNMT mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:6,591,804...6,623,821
|
|
G |
Hnrnpa2b1 |
heterogeneous nuclear ribonucleoprotein A2/B1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of HNRNPA2B1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:81,867,354...81,875,886
|
|
G |
Hnrnpc |
heterogeneous nuclear ribonucleoprotein C |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of HNRNPC mRNA |
CTD |
PMID:26377693 |
|
NCBI chr15:24,779,593...24,809,213
|
|
G |
Hnrnpdl |
heterogeneous nuclear ribonucleoprotein D-like |
increases expression |
ISO |
benz(a)anthracene results in increased expression of HNRNPDL mRNA |
CTD |
PMID:26377693 |
|
NCBI chr14:9,861,716...9,867,945
|
|
G |
Hnrnpf |
heterogeneous nuclear ribonucleoprotein F |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HNRNPF mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 4:152,755,668...152,776,867
|
|
G |
Hnrnph1 |
heterogeneous nuclear ribonucleoprotein H1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of HNRNPH1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:34,692,868...34,702,849
|
|
G |
Hps1 |
HPS1, biogenesis of lysosomal organelles complex 3 subunit 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HPS1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:241,551,180...241,577,292
|
|
G |
Hsd3b7 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of HSD3B7 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:191,842,688...191,845,919
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of HSPA1A mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HSPA1A mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr20:3,875,411...3,877,866
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of HSPA8 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:50,080,514...50,084,376
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of HSPD1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 9:64,073,610...64,084,332
|
|
G |
Htatip2 |
HIV-1 Tat interactive protein 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HTATIP2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:108,609,424...108,624,810
|
|
G |
Htatsf1 |
HIV-1 Tat specific factor 1 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of HTATSF1 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HTATSF1 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr X:134,935,426...134,949,607
|
|
G |
Hunk |
hormonally upregulated Neu-associated kinase |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of HUNK mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HUNK mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr11:43,127,244...43,244,502
|
|
G |
Hyal1 |
hyaluronidase 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of HYAL1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:108,250,668...108,254,519
|
|
G |
Ica1 |
islet cell autoantigen 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ICA1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 4:36,656,475...36,804,705
|
|
G |
Icoslg |
inducible T-cell co-stimulator ligand |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ICOSL mRNA |
CTD |
PMID:26377693 |
|
NCBI chr20:10,600,420...10,610,718
|
|
G |
Id1 |
inhibitor of DNA binding 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ID1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 3:161,671,525...161,672,691
|
|
G |
Idua |
alpha-L-iduronidase |
increases expression |
ISO |
benz(a)anthracene results in increased expression of IDUA mRNA |
CTD |
PMID:26377693 |
|
NCBI chr14:1,031,588...1,059,494
|
|
G |
Ier3 |
immediate early response 3 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of IER3 mRNA |
CTD |
PMID:22579512 |
|
NCBI chr20:2,933,173...2,934,377
|
|
G |
Ier5 |
immediate early response 5 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of IER5 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr13:67,270,134...67,272,226
|
|
G |
Iffo1 |
intermediate filament family orphan 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of IFFO1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:157,945,075...157,962,302
|
|
G |
Ifi27l2a |
interferon, alpha-inducible protein 27 like 2A |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of IFI27L2A mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 6:122,598,872...122,600,358
|
|
G |
Ifi44 |
interferon-induced protein 44 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of IFI44 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 2:243,286,050...243,303,869
|
|
G |
Ifit3 |
interferon-induced protein with tetratricopeptide repeats 3 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of IFIT3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:232,114,166...232,119,311
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of IGFBP5 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 9:74,452,371...74,464,953
|
|
G |
Igflr1 |
IGF-like family receptor 1 |
affects expression |
ISO |
benz(a)anthracene affects the expression of IGFLR1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:85,818,428...85,821,032
|
|
G |
Igsf3 |
immunoglobulin superfamily, member 3 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IGSF3 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 2:188,811,394...188,899,645
|
|
G |
Igsf6 |
immunoglobulin superfamily, member 6 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of IGSF6 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:175,610,167...175,620,662
|
|
G |
Ikzf4 |
IKAROS family zinc finger 4 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IKZF4 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 7:1,063,283...1,102,940
|
|
G |
Il18r1 |
interleukin 18 receptor 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IL18R1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 9:42,727,416...42,760,971
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
benz(a)anthracene results in increased expression of IL1A mRNA |
CTD |
PMID:8156173 |
|
NCBI chr 3:136,979,804...136,990,236
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of IL1B mRNA |
CTD |
PMID:8156173 |
|
NCBI chr 3:137,030,200...137,036,581
|
|
G |
Il4i1 |
interleukin 4 induced 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of IL4I1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:95,299,457...95,324,564
|
|
G |
Il6 |
interleukin 6 |
increases secretion multiple interactions increases expression |
ISO |
benz(a)anthracene results in increased secretion of IL6 protein [benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6 mRNA; [benz(a)anthracene co-treated with TNF protein] results in increased secretion of IL6 protein; AHR protein affects the reaction [[benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6]; Curcumin inhibits the reaction [[benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6 mRNA]; RELA protein affects the reaction [[benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6]; Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of IL6 mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased secretion of IL6 protein] |
CTD |
PMID:8156173 PMID:22643241 PMID:23396138 PMID:25433334 |
|
NCBI chr 4:5,889,999...5,894,575
|
|
G |
Il7r |
interleukin 7 receptor |
increases expression |
ISO |
benz(a)anthracene results in increased expression of IL7R mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 2:58,452,393...58,477,757
|
|
G |
Ilf2 |
interleukin enhancer binding factor 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ILF2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 2:178,256,927...178,268,773
|
|
G |
Ilrun |
inflammation and lipid regulator with UBA-like and NBR1-like domains |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of ILRUN mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ILRUN mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr20:5,809,931...5,876,197
|
|
G |
Inafm2 |
InaF motif containing 2 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of INAFM2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:105,728,208...105,733,766
|
|
G |
Inka2 |
inka box actin regulator 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of INKA2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 2:193,185,275...193,200,643
|
|
G |
Ino80b |
INO80 complex subunit B |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of INO80B mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 4:117,185,427...117,188,930
|
|
G |
Inpp5k |
inositol polyphosphate-5-phosphatase K |
increases expression |
ISO |
benz(a)anthracene results in increased expression of INPP5K mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:60,474,262...60,495,813
|
|
G |
Ints6l |
integrator complex subunit 6 like |
increases expression |
ISO |
benz(a)anthracene results in increased expression of INTS6L mRNA |
CTD |
PMID:26377693 |
|
NCBI chr X:134,258,117...134,325,706
|
|
G |
Iqce |
IQ motif containing E |
increases expression |
ISO |
benz(a)anthracene results in increased expression of IQCE mRNA |
CTD |
PMID:26377693 |
|
NCBI chr12:13,943,290...13,982,708
|
|
G |
Iqsec3 |
IQ motif and Sec7 domain ArfGEF 3 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of IQSEC3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:154,610,933...154,707,310
|
|
G |
Irag2 |
inositol 1,4,5-triphosphate receptor associated 2 |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of IRAG2 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of IRAG2 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 4:178,088,902...178,143,569
|
|
G |
Irf2bp2 |
interferon regulatory factor 2 binding protein 2 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of IRF2BP2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr19:54,559,417...54,565,096
|
|
G |
Irf2bpl |
interferon regulatory factor 2 binding protein-like |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IRF2BPL mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 6:112,258,149...112,262,264
|
|
G |
Irf7 |
interferon regulatory factor 7 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of IRF7 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:205,796,956...205,800,543
|
|
G |
Isg15 |
ISG15 ubiquitin-like modifier |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of ISG15 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:172,066,369...172,067,656
|
|
G |
Itga1 |
integrin subunit alpha 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ITGA1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 2:48,379,181...48,545,336
|
|
G |
Itga2 |
integrin subunit alpha 2 |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of ITGA2 mRNA Acetylcysteine inhibits the reaction [benz(a)anthracene results in increased expression of ITGA2 mRNA]; SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of ITGA2 mRNA] |
CTD |
PMID:21635667 |
|
NCBI chr 2:46,520,345...46,621,487
|
|
G |
Itga7 |
integrin subunit alpha 7 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ITGA7 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 7:1,360,125...1,388,886
|
|
G |
Itgb1 |
integrin subunit beta 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of ITGB1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr19:73,602,277...73,650,271
|
|
G |
Itih4 |
inter-alpha-trypsin inhibitor heavy chain 4 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of ITIH4 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr16:6,080,539...6,095,710
|
|
G |
Itpripl2 |
ITPRIP like 2 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of ITPRIPL2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:172,801,152...172,803,047
|
|
G |
Itsn1 |
intersectin 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of ITSN1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr11:44,464,515...44,646,598
|
|
G |
Izumo4 |
IZUMO family member 4 |
affects expression |
ISO |
benz(a)anthracene affects the expression of IZUMO4 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 7:9,007,276...9,010,428
|
|
G |
Jade1 |
jade family PHD finger 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of JADE1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 2:124,543,233...124,596,361
|
|
G |
Jak3 |
Janus kinase 3 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of JAK3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr16:18,418,807...18,432,515
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [benz(a)anthracene results in increased expression of JUN mRNA]; SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of JUN mRNA] |
CTD |
PMID:21635667 |
|
NCBI chr 5:115,009,900...115,012,993
|
|
G |
Kank4 |
KN motif and ankyrin repeat domains 4 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KANK4 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 5:118,516,994...118,581,024
|
|
G |
Kazn |
kazrin, periplakin interacting protein |
increases expression |
ISO |
benz(a)anthracene results in increased expression of KAZN mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:159,675,803...160,666,084
|
|
G |
Kcne3 |
potassium voltage-gated channel subfamily E regulatory subunit 3 |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of KCNE3 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KCNE3 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 1:154,523,903...154,530,865
|
|
G |
Kctd12b |
potassium channel tetramerization domain containing 12b |
increases expression |
ISO |
benz(a)anthracene results in increased expression of KCTD12B mRNA |
CTD |
PMID:26377693 |
|
NCBI chr X:17,643,707...17,654,820
|
|
G |
Kif21b |
kinesin family member 21B |
increases expression |
ISO |
benz(a)anthracene results in increased expression of KIF21B mRNA |
CTD |
PMID:26377693 |
|
NCBI chr13:47,576,129...47,626,112
|
|
G |
Kif26b |
kinesin family member 26B |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KIF26B mRNA |
CTD |
PMID:27858113 |
|
NCBI chr13:90,282,821...90,689,058
|
|
G |
Kifc2 |
kinesin family member C2 |
affects expression |
ISO |
benz(a)anthracene affects the expression of KIFC2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 7:108,380,634...108,388,364
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
increases expression |
ISO |
benz(a)anthracene results in increased expression of KIT mRNA |
CTD |
PMID:26377693 |
|
NCBI chr14:32,901,615...32,978,895
|
|
G |
Kitlg |
KIT ligand |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of KITL mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KITL mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 7:36,782,621...36,863,796
|
|
G |
Klf12 |
KLF transcription factor 12 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of KLF12 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr15:83,037,548...83,469,998
|
|
G |
Klf5 |
KLF transcription factor 5 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of KLF5 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr15:76,060,320...76,079,445
|
|
G |
Klhdc8b |
kelch domain containing 8B |
affects expression |
ISO |
benz(a)anthracene affects the expression of KLHDC8B mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:109,141,594...109,146,584
|
|
G |
Klhdc9 |
kelch domain containing 9 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of KLHDC9 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr13:83,790,390...83,794,080
|
|
G |
Klhl5 |
kelch-like family member 5 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KLHL5 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr14:43,497,915...43,565,833
|
|
G |
Klhl6 |
kelch-like family member 6 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KLHL6 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr11:80,970,917...81,010,593
|
|
G |
Klrd1 |
killer cell lectin like receptor D1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of KLRD1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:163,044,920...163,056,568
|
|
G |
Kmt2d |
lysine methyltransferase 2D |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KMT2D mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 7:129,980,744...130,022,088
|
|
G |
Kmt5a |
lysine methyltransferase 5A |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of KMT5A mRNA |
CTD |
PMID:26377693 |
|
NCBI chr12:37,800,339...37,823,706
|
|
G |
Kmt5b |
lysine methyltransferase 5B |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KMT5B mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:210,429,672...210,479,042
|
|
G |
Krba1 |
KRAB-A domain containing 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of KRBA1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:77,341,654...77,363,075
|
|
G |
Krt15 |
keratin 15 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KRT15 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr10:85,066,797...85,070,614
|
|
G |
Krt31 |
keratin 31 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of KRT31 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:85,479,533...85,483,300
|
|
G |
Krtcap3 |
keratinocyte associated protein 3 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of KRTCAP3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 6:25,120,938...25,122,522
|
|
G |
Kyat1 |
kynurenine aminotransferase 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of KYAT1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:33,857,407...33,891,153
|
|
G |
Lama1 |
laminin subunit alpha 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LAMA1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 9:115,139,548...115,263,620
|
|
G |
Lasp1 |
LIM and SH3 protein 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LASP1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr10:83,290,820...83,331,989
|
|
G |
Lca5l |
lebercilin LCA5 like |
increases expression |
ISO |
benz(a)anthracene results in increased expression of LCA5L mRNA |
CTD |
PMID:26377693 |
|
NCBI chr11:35,460,646...35,495,133
|
|
G |
Lcorl |
ligand dependent nuclear receptor corepressor-like |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of LCORL mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LCORL mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr14:69,482,919...69,620,269
|
|
G |
Lefty1 |
left right determination factor 1 |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of LEFTY1 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LEFTY1 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr13:92,649,226...92,659,722
|
|
G |
Leng8 |
leukocyte receptor cluster member 8 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of LENG8 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:79,113,038...79,124,868
|
|
G |
Leo1 |
LEO1 homolog, Paf1/RNA polymerase II complex component |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of LEO1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:76,199,547...76,223,983
|
|
G |
Lepr |
leptin receptor |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LEPR mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 5:121,409,735...121,593,201
|
|
G |
Lgals1 |
galectin 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of LGALS1 mRNA |
CTD |
PMID:22579512 |
|
NCBI chr 7:112,365,695...112,368,801
|
|
G |
Lgals4 |
galectin 4 |
affects expression |
ISO |
benz(a)anthracene affects the expression of LGALS4 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:84,124,766...84,132,481
|
|
G |
Lhfpl3 |
LHFPL tetraspan subfamily member 3 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LHFPL3 mRNA |
CTD |
PMID:27858113 |
|
|
|
G |
Lime1 |
Lck interacting transmembrane adaptor 1 |
affects expression |
ISO |
benz(a)anthracene affects the expression of LIME1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:168,490,535...168,496,627
|
|
G |
Lipa |
lipase A, lysosomal acid type |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of LIPA mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:241,437,524...241,470,936
|
|
G |
Lpin1 |
lipin 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LPIN1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 6:45,039,110...45,145,845
|
|
G |
Lratd1 |
LRAT domain containing 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of LRATD1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 6:36,916,969...36,922,143
|
|
G |
Lrp12 |
LDL receptor related protein 12 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of LRP12 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 7:70,941,068...71,012,409
|
|
G |
Lrrc36 |
leucine rich repeat containing 36 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of LRRC36 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr19:33,292,074...33,342,426
|
|
G |
Lrrc45 |
leucine rich repeat containing 45 |
affects expression |
ISO |
benz(a)anthracene affects the expression of LRRC45 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:106,492,846...106,500,751
|
|
G |
Lrrc71 |
leucine rich repeat containing 71 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of LRRC71 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 2:173,194,792...173,207,448
|
|
G |
Lrrc75b |
leucine rich repeat containing 75B |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LRRC75B mRNA |
CTD |
PMID:27858113 |
|
NCBI chr20:13,100,302...13,106,503
|
|
G |
Lrrk1 |
leucine-rich repeat kinase 1 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of LRRK1 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LRRK1 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 1:129,254,815...129,390,217
|
|
G |
Lrrn4 |
leucine rich repeat neuronal 4 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of LRRN4 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:120,138,093...120,150,877
|
|
G |
Lrtm2 |
leucine-rich repeats and transmembrane domains 2 |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of LRTM2 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LRTM2 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 4:152,485,863...152,508,248
|
|
G |
Lsm14b |
LSM family member 14B |
increases expression |
ISO |
benz(a)anthracene results in increased expression of LSM14B mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:167,125,633...167,136,417
|
|
G |
Lst1 |
leukocyte specific transcript 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LST1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr20:3,634,680...3,639,731
|
|
G |
Ltc4s |
leukotriene C4 synthase |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LTC4S mRNA |
CTD |
PMID:27858113 |
|
NCBI chr10:35,060,002...35,066,466
|
|
G |
Luc7l3 |
LUC7-like 3 pre-mRNA splicing factor |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of LUC7L3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:79,737,457...79,773,478
|
|
G |
Lum |
lumican |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LUM mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 7:34,245,323...34,252,510
|
|
G |
Ly6a |
lymphocyte antigen 6 family member A |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LY6A mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 7:107,177,191...107,189,436
|
|
G |
Lyve1 |
lymphatic vessel endothelial hyaluronan receptor 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LYVE1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:164,962,872...164,976,309
|
|
G |
Lyzl4 |
lysozyme-like 4 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of LYZL4 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:121,248,129...121,255,366
|
|
G |
Lztr1 |
leucine zipper like post translational regulator 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of LZTR1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr11:83,487,717...83,503,896
|
|
G |
Lzts3 |
leucine zipper tumor suppressor family member 3 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LZTS3 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 3:117,850,286...117,861,132
|
|
G |
Mageh1 |
MAGE family member H1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of MAGEH1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr X:18,350,015...18,351,271
|
|
G |
Magi3 |
membrane associated guanylate kinase, WW and PDZ domain containing 3 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MAGI3 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 2:191,514,726...191,717,048
|
|
G |
Magt1 |
magnesium transporter 1 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of MAGT1 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MAGT1 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr X:75,104,040...75,145,247
|
|
G |
Malt1 |
MALT1 paracaspase |
increases expression |
ISO |
benz(a)anthracene results in increased expression of MALT1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr18:61,212,290...61,266,272
|
|
G |
Manf |
mesencephalic astrocyte-derived neurotrophic factor |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of MANF mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:107,500,856...107,551,595
|
|
G |
Maoa |
monoamine oxidase A |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MAOA mRNA |
CTD |
PMID:27858113 |
|
NCBI chr X:8,615,239...8,681,372
|
|
G |
Map3k14 |
mitogen-activated protein kinase kinase kinase 14 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of MAP3K14 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:88,665,417...88,715,669
|
|
G |
Map4k2 |
mitogen activated protein kinase kinase kinase kinase 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of MAP4K2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:213,074,360...213,090,042
|
|
G |
Map4k4 |
mitogen-activated protein kinase kinase kinase kinase 4 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MAP4K4 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 9:49,696,573...49,822,353
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions increases phosphorylation |
ISO |
Acetylcysteine inhibits the reaction [benz(a)anthracene results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [benz(a)anthracene results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:21635667 |
|
NCBI chr20:6,751,288...6,812,294
|
|
G |
Mapk8ip3 |
mitogen-activated protein kinase 8 interacting protein 3 |
affects expression |
ISO |
benz(a)anthracene affects the expression of MAPK8IP3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:13,918,417...13,958,335
|
|
G |
Marchf1 |
membrane associated ring-CH-type finger 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of MARCHF1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr16:23,255,551...24,114,290
|
|
G |
Marco |
macrophage receptor with collagenous structure |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MARCO mRNA |
CTD |
PMID:27858113 |
|
NCBI chr13:31,616,278...31,648,521
|
|
G |
Marveld3 |
MARVEL domain containing 3 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MARVELD3 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr19:37,908,727...37,923,420
|
|
G |
Mat1a |
methionine adenosyltransferase 1A |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MAT1A mRNA |
CTD |
PMID:27858113 |
|
NCBI chr16:16,983,084...17,001,284
|
|
G |
Mat2a |
methionine adenosyltransferase 2A |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of MAT2A mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:106,048,043...106,053,612
|
|
G |
Mbip |
MAP3K12 binding inhibitory protein 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of MBIP mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 6:73,808,133...73,825,394
|
|
G |
Mboat2 |
membrane bound O-acyltransferase domain containing 2 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of MBOAT2 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MBOAT2 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 6:41,471,135...41,597,599
|
|
G |
Mcam |
melanoma cell adhesion molecule |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MCAM mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 8:44,479,391...44,487,575
|
|
G |
Mcm6 |
minichromosome maintenance complex component 6 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of MCM6 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr13:42,379,161...42,404,352
|
|
G |
Mcoln3 |
mucolipin TRP cation channel 3 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of MCOLN3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 2:235,008,716...235,042,885
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MDM2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 7:55,176,558...55,201,757
|
|
G |
Mdm4 |
MDM4 regulator of p53 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of MDM4 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MDM4 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr13:46,922,236...47,068,241
|
|
G |
Mdn1 |
midasin AAA ATPase 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MDN1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 5:51,851,785...51,982,688
|
|
G |
Mecom |
MDS1 and EVI1 complex locus |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of MECOM mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 2:114,837,815...115,393,052
|
|
G |
Meg3 |
maternally expressed 3 |
affects expression |
ISO |
benz(a)anthracene affects the expression of MEG3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 6:128,491,808...128,524,010
|
|
G |
Megf6 |
multiple EGF-like-domains 6 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of MEGF6 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:170,020,699...170,121,557
|
|
G |
Meiob |
meiosis specific with OB-fold |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of MEIOB mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:13,833,170...13,865,684
|
|
G |
Mesp1 |
mesoderm posterior bHLH transcription factor 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of MESP1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:143,147,671...143,149,189
|
|
G |
Mettl18 |
methyltransferase 18, RPL3 N3(tau)-histidine |
increases expression |
ISO |
benz(a)anthracene results in increased expression of METTL18 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr13:76,345,888...76,348,798
|
|
G |
Mfap2 |
microfibril associated protein 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MFAP2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 5:153,312,068...153,320,266
|
|
G |
Mfap4 |
microfibril associated protein 4 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MFAP4 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr10:46,666,552...46,669,613
|
|
G |
Mfsd2a |
MFSD2 lysolipid transporter A, lysophospholipid |
increases expression |
ISO |
benz(a)anthracene results in increased expression of MFSD2A mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:140,510,933...140,525,828
|
|
G |
Mgat2 |
alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of MGAT2 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MGAT2 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 6:87,656,360...87,658,849
|
|
G |
Mgll |
monoglyceride lipase |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MGLL mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 4:122,749,436...122,851,440
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MGMT mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:201,140,832...201,367,481
|
|
G |
Mia3 |
MIA SH3 domain ER export factor 3 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of MIA3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr13:94,970,421...95,012,071
|
|
G |
Mical1 |
microtubule associated monooxygenase, calponin and LIM domain containing 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of MICAL1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr20:46,547,983...46,568,487
|
|
G |
Mideas |
mitotic deacetylase associated SANT domain protein |
multiple interactions decreases expression |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MIDEAS mRNA benz(a)anthracene results in decreased expression of MIDEAS mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 6:103,784,779...103,854,470
|
|
G |
Mir181d |
microRNA 181d |
increases expression |
ISO |
benz(a)anthracene results in increased expression of MIR181D mRNA |
CTD |
PMID:23993976 |
|
NCBI chr19:23,983,706...23,983,788
|
|
G |
Mir200c |
microRNA 200c |
increases expression |
ISO |
benz(a)anthracene results in increased expression of MIR200C mRNA |
CTD |
PMID:23993976 |
|
NCBI chr 4:157,523,679...157,523,747
|
|
G |
Mir22 |
microRNA 22 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of MIR22 mRNA |
CTD |
PMID:23993976 |
|
NCBI chr10:60,307,039...60,307,133
|
|
G |
Mir221 |
microRNA 221 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of MIR221 mRNA |
CTD |
PMID:23993976 |
|
NCBI chr X:6,023,182...6,023,290
|
|
G |
Mir23b |
microRNA 23b |
increases expression |
ISO |
benz(a)anthracene results in increased expression of MIR23B mRNA |
CTD |
PMID:23993976 |
|
NCBI chr17:1,813,667...1,813,763
|
|
G |
Mir33 |
microRNA 33 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of MIR33A mRNA |
CTD |
PMID:23993976 |
|
NCBI chr 7:115,593,952...115,594,020
|
|
G |
Mirlet7b |
microRNA let-7b |
increases expression |
ISO |
benz(a)anthracene results in increased expression of MIRLET7B mRNA |
CTD |
PMID:23993976 |
|
NCBI chr 7:116,804,186...116,804,270
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
[benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with Benzo(a)pyrene co-treated with chrysene] results in increased expression of MKI67 protein; [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MKI67 mRNA |
CTD |
PMID:27858113 PMID:38237855 |
|
NCBI chr 1:199,926,150...199,952,847
|
|
G |
Mkks |
MKKS centrosomal shuttling protein |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of MKKS mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:144,654,563...144,672,831
|
|
G |
Mlph |
melanophilin |
increases expression |
ISO |
benz(a)anthracene results in increased expression of MLPH mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 9:98,955,036...98,990,566
|
|
G |
Mmd2 |
monocyte to macrophage differentiation-associated 2 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of MMD2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr12:17,075,870...17,123,255
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MMP14 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr15:27,887,795...27,897,020
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of MMP2 mRNA Acetylcysteine inhibits the reaction [benz(a)anthracene results in increased expression of MMP2 mRNA]; SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of MMP2 mRNA] |
CTD |
PMID:21635667 |
|
NCBI chr19:30,327,643...30,355,856
|
|
G |
Mmp8 |
matrix metallopeptidase 8 |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of MMP8 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MMP8 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 8:4,724,009...4,733,864
|
|
G |
Mmrn2 |
multimerin 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MMRN2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr16:9,705,925...9,727,405
|
|
G |
Mnda |
myeloid cell nuclear differentiation antigen |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of MNDA mRNA |
CTD |
PMID:26377693 |
|
NCBI chr13:86,017,888...86,035,556
|
|
G |
Morc4 |
MORC family CW-type zinc finger 4 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of MORC4 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr X:103,477,366...103,529,026
|
|
G |
Mpeg1 |
macrophage expressed 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MPEG1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:209,452,176...209,456,692
|
|
G |
Mphosph10 |
M-phase phosphoprotein 10 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of MPHOSPH10 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:117,948,134...117,964,149
|
|
G |
Mrln |
myoregulin |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of MRLN mRNA |
CTD |
PMID:26377693 |
|
NCBI chr20:18,406,789...18,423,805
|
|
G |
Mrps6 |
mitochondrial ribosomal protein S6 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of MRPS6 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr11:31,295,358...31,348,483
|
|
G |
Ms4a1 |
membrane spanning 4-domains A1 |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of MS4A1 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MS4A1 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 1:207,906,370...207,927,028
|
|
G |
Ms4a4a |
membrane spanning 4-domains A4A |
increases expression |
ISO |
benz(a)anthracene results in increased expression of MS4A4A mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:208,060,507...208,085,121
|
|
G |
Ms4a8 |
membrane spanning 4-domains A8 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of MS4A8A mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:207,730,665...207,744,260
|
|
G |
Msln |
mesothelin |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of MSLN mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MSLN mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr10:14,771,946...14,781,382
|
|
G |
Msr1 |
macrophage scavenger receptor 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MSR1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr16:52,717,775...52,803,602
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of COX1 mRNA |
CTD |
PMID:26377693 |
|
|
|
G |
Mt-nd4l |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ND4L mRNA |
CTD |
PMID:27858113 |
|
NCBI chr MT:9,870...10,166 NCBI chr MT:9,870...10,166 NCBI chr MT:9,870...10,166 NCBI chr MT:9,870...10,166 NCBI chr MT:9,870...10,166 NCBI chr MT:9,870...10,166 NCBI chr MT:9,870...10,166 NCBI chr MT:9,870...10,166 NCBI chr MT:9,870...10,166 NCBI chr MT:9,870...10,166 NCBI chr MT:9,870...10,166 NCBI chr MT:9,870...10,166 NCBI chr MT:9,870...10,166
|
|
G |
Mt-nd6 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of ND6 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ND6 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
|
|
G |
Mthfd1l |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of MTHFD1L mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MTHFD1L mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 1:40,443,926...40,632,911
|
|
G |
Mtmr10 |
myotubularin related protein 10 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MTMR10 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:117,859,355...117,910,839
|
|
G |
Mtx3 |
metaxin 3 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of MTX3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 2:24,066,332...24,079,708
|
|
G |
Muc4 |
mucin 4, cell surface associated |
increases expression |
ISO |
benz(a)anthracene results in increased expression of MUC4 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr11:68,008,245...68,053,242
|
|
G |
Mx2 |
MX dynamin like GTPase 2 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of MX2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr11:50,375,101...50,399,373
|
|
G |
Myadm |
myeloid-associated differentiation marker |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of MYADM mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MYADM mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 1:65,864,180...65,874,701
|
|
G |
Myo1g |
myosin IG |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of MYO1G mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MYO1G mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr14:81,386,701...81,401,843
|
|
G |
Myom3 |
myomesin 3 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of MYOM3 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:147,992,737...148,043,282
|
|
G |
Nap1l4 |
nucleosome assembly protein 1-like 4 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of NAP1L4 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:198,709,697...198,746,093
|
|
G |
Nat8 |
N-acetyltransferase 8 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NAT8 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 4:118,279,521...118,284,671
|
|
G |
Nat8b |
N-acetyltransferase 8B |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of NAT8B mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 4:118,359,445...118,364,351
|
|
G |
Nbeal1 |
neurobeachin-like 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of NBEAL1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 9:69,069,326...69,237,932
|
|
G |
Ncaph |
non-SMC condensin I complex, subunit H |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NCAPH mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 3:134,825,271...134,852,502
|
|
G |
Ncbp2 |
nuclear cap binding protein subunit 2 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of NCBP2 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NCBP2 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr11:68,821,026...68,829,863
|
|
G |
Ncbp3 |
nuclear cap binding subunit 3 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NCBP3 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr10:57,665,716...57,695,432
|
|
G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of NCEH1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 2:112,003,677...112,064,274
|
|
G |
Ndc80 |
NDC80 kinetochore complex component |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of NDC80 mRNA |
CTD |
PMID:22579512 |
|
NCBI chr 9:118,853,806...118,887,582
|
|
G |
Ndor1 |
NADPH dependent diflavin oxidoreductase 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of NDOR1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:28,460,787...28,469,018
|
|
G |
Neat1 |
nuclear paraspeckle assembly transcript 1 |
affects expression |
ISO |
benz(a)anthracene affects the expression of NEAT1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:203,129,229...203,140,014
|
|
G |
Neb |
nebulin |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of NEB mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:36,613,677...36,811,618
|
|
G |
Necab1 |
N-terminal EF-hand calcium binding protein 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of NECAB1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:28,357,859...28,578,642
|
|
G |
Nectin1 |
nectin cell adhesion molecule 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PVRL1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 8:44,101,776...44,164,863
|
|
G |
Nedd9 |
neural precursor cell expressed, developmentally down-regulated 9 |
multiple interactions |
ISO |
[benz(a)anthracene co-treated with TNF protein] results in increased expression of NEDD9 mRNA |
CTD |
PMID:23396138 |
|
NCBI chr17:23,289,793...23,468,026
|
|
G |
Nemp2 |
nuclear envelope integral membrane protein 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of NEMP2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 9:48,861,252...48,880,565
|
|
G |
Neu2 |
neuraminidase 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NEU2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 9:95,666,338...95,715,209
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NFATC1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr18:76,321,386...76,430,997
|
|
G |
Nfe2 |
nuclear factor, erythroid 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NFE2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 7:134,382,758...134,395,364
|
|
G |
Nfil3 |
nuclear factor, interleukin 3 regulated |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of NFIL3 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NFIL3 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr17:12,432,376...12,447,605
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[benz(a)anthracene co-treated with TNF protein] results in increased phosphorylation of and results in increased degradation of NFKBIA protein |
CTD |
PMID:23396138 |
|
NCBI chr 6:78,593,844...78,597,307
|
|
G |
Nfkbid |
NFKB inhibitor delta |
increases expression |
ISO |
benz(a)anthracene results in increased expression of NFKBID mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 1:85,679,353...85,690,415
|
|
G |
Nfrkb |
nuclear factor related to kappa B binding protein |
increases expression |
ISO |
benz(a)anthracene results in increased expression of NFRKB mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:38,089,574...38,121,506
|
|
G |
Ngfr |
nerve growth factor receptor |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TNFRSF10B mRNA |
CTD |
PMID:27858113 |
|
NCBI chr10:81,012,077...81,030,305
|
|
G |
Nhej1 |
nonhomologous end-joining factor 1 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of NHEJ1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 9:76,526,322...76,622,488
|
|
G |
Nherf1 |
NHERF family PDZ scaffold protein 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of NHERF1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:100,403,189...100,420,290
|
|
G |
Nhlrc2 |
NHL repeat containing 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NHLRC2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 1:265,594,915...265,655,647
|
|
G |
Nktr |
natural killer cell triggering receptor |
affects expression multiple interactions |
ISO |
benz(a)anthracene affects the expression of NKTR mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NKTR mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 8:121,380,010...121,420,495
|
|
G |
Nlrc5 |
NLR family, CARD domain containing 5 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of NLRC5 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr19:10,477,638...10,581,023
|
|
G |
Nostrin |
nitric oxide synthase trafficking |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of NOSTRIN mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 3:53,904,746...53,970,995
|
|
G |
Notch1 |
notch receptor 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NOTCH1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 3:29,676,040...29,721,613
|
|
G |
Noxo1 |
NADPH oxidase organizer 1 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of NOXO1 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:13,723,253...13,726,008
|
|
G |
Nphp1 |
nephrocystin 1 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of NPHP1 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NPHP1 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr 3:135,413,927...135,469,505
|
|
G |
Npr3 |
natriuretic peptide receptor 3 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NPR3 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 2:60,865,483...60,933,432
|
|
G |
Npy1r |
neuropeptide Y receptor Y1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NPY1R mRNA |
CTD |
PMID:27858113 |
|
NCBI chr16:27,804,416...27,814,070
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases activity increases expression multiple interactions |
ISO EXP |
benz(a)anthracene results in increased activity of NQO1 protein benz(a)anthracene results in increased expression of NQO1 mRNA 1-(5-isoquinolinylsulfonyl)-3-methylpiperazine inhibits the reaction [benz(a)anthracene results in increased activity of NQO1 protein]; Dexamethasone inhibits the reaction [benz(a)anthracene results in increased activity of NQO1 protein]; Dexamethasone inhibits the reaction [benz(a)anthracene results in increased expression of NQO1 mRNA]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [benz(a)anthracene results in increased activity of NQO1 protein]]; Staurosporine inhibits the reaction [benz(a)anthracene results in increased activity of NQO1 protein] |
CTD |
PMID:7587946 PMID:9029048 PMID:17253728 |
|
NCBI chr19:52,205,374...52,220,267
|
|
G |
Nr1d1 |
nuclear receptor subfamily 1, group D, member 1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NR1D1 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr10:84,224,599...84,231,812
|
|
G |
Nr1d2 |
nuclear receptor subfamily 1, group D, member 2 |
increases expression multiple interactions |
ISO |
benz(a)anthracene results in increased expression of NR1D2 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NR1D2 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr15:7,524,257...7,550,553
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
EXP |
NR3C1 protein promotes the reaction [Dexamethasone promotes the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]] |
CTD |
PMID:2916850 |
|
NCBI chr18:31,522,783...31,644,508
|
|
G |
Nrbp2 |
nuclear receptor binding protein 2 |
decreases expression |
ISO |
benz(a)anthracene results in decreased expression of NRBP2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 7:109,679,330...109,685,656
|
|
G |
Nrcam |
neuronal cell adhesion molecule |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NRCAM mRNA |
CTD |
PMID:27858113 |
|
NCBI chr 6:61,402,813...61,698,536
|
|
G |
Nrg4 |
neuregulin 4 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of NRG4 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 8:55,586,253...55,677,829
|
|
G |
Nsd1 |
nuclear receptor binding SET domain protein 1 |
decreases expression multiple interactions |
ISO |
benz(a)anthracene results in decreased expression of NSD1 mRNA [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NSD1 mRNA |
CTD |
PMID:26377693 PMID:27858113 |
|
NCBI chr17:9,311,963...9,426,373
|
|
G |
Nsg2 |
neuronal vesicle trafficking associated 2 |
increases expression |
ISO |
benz(a)anthracene results in increased expression of NSG2 mRNA |
CTD |
PMID:26377693 |
|
NCBI chr10:15,601,594...15,661,441
|
|
G |
Nsmaf |
neutral sphingomyelinase activation associated factor |
increases expression |
ISO |
benz(a)anthracene results in increased expression of NSMAF mRNA |
CTD |
PMID:26377693 |
|
NCBI chr 5:24,315,319...24,378,346
|
|
G |
Nt5dc2 |
5'-nucleotidase domain containing 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NT5DC2 mRNA |
CTD |
PMID:27858113 |
|
NCBI chr16:6,3 |